



History and Ecology of R

Martyn Plummer

International Agency for
Research on Cancer

SPE 2017, Tartu

International Agency for Research on Cancer



Pre-history History Present Future?

Programming with Data

"We wanted users to be able to begin in an interactive environment, where they did not consciously think of themselves as programming. Then as their needs became clearer and their sophistication increased, they should be able to slide gradually into programming." – John Chambers, *Stages in the Evolution of S*

This philosophy was later articulated explicitly in *Programming With Data* (Chambers, 1998) as a kind of mission statement for S
To turn ideas into software, quickly and faithfully

International Agency for Research on Cancer



Pre-history History Present Future?

Pre-history

Before there was R, there was S.

International Agency for Research on Cancer



Pre-history History Present Future?

The "Green Book"



Key features of S version 4 were outlined in Chambers, *Programming with Data* (1998).

- S as a programming language
- Introduced formal classes and methods, which were later introduced into R by John Chambers himself.

International Agency for Research on Cancer



Pre-history History Present Future?

The S language

Developed at AT&T Bell laboratories by Rick Becker, John Chambers, Doug Dunn, Paul Tukey, Graham Wilkinson.

Version 1	1976–1980	Honeywell GCOS, Fortran-based
Version 2	1980–1988	Unix; Macros, Interface Language
	1981–1986	QPE (Quantitative Programming Environment)
	1984–	General outside licensing; books
Version 3	1988–1998	C-based; S functions and objects
	1991–	Statistical models; informal classes and methods
Version 4	1998	Formal class-method model; connections; large objects
	1991–	Interfaces to Java, Corba?

Source: Stages in the Evolution of S <http://ect.bell-labs.com/s1/S/history.html>

International Agency for Research on Cancer



Pre-history History Present Future?

S-PLUS


- AT&T was a regulated monopoly with limited ability to exploit creations of Bell Labs.
- S source code was supplied for free to universities
- After the break up of AT&T in 1984 it became possible for them to sell S.
- S-PLUS was a commercially available form of S licensed to Statistical Sciences (later Mathsoft, later Insightful) with added features:
 - GUI, survival analysis, non-linear mixed effects, Trellis graphics, ...

International Agency for Research on Cancer



Pre-history History Present Future?

The "Blue Book" and the "White Book"



Key features of S version 3 outlined in two books:

- Becker, Chambers and Wilks, *The New S Language: A Programming Environment for Statistical Analysis and Graphics* (1988)
 - Functions and objects
- Chambers and Hastie (Eds), *Statistical Models in S* (1992)
 - Data frames, formulae

These books were later used as a prototype for R.

International Agency for Research on Cancer



Pre-history History Present Future?

The Rise and Fall of S-PLUS

- 1988. Statistical Science releases first version of S-PLUS.
- 1993. Acquires exclusive license to distribute S. Merges with Mathsoft.
- 2001. Changes name to Insightful.
- 2004. Purchases S language for \$2 million.
- 2008. Insightful sold to TIBCO. S-PLUS incorporated into TIBCO Spotfire.

International Agency for Research on Cancer



Pre-history

History

Present

Future?

History

How R started, and how it turned into an S clone

International Agency for Research on Cancer
World Health Organization


Pre-history

History

Present

Future?

A Souvenir



International Agency for Res
World Health Organization


Pre-history

History

Present

Future?

The Dawn of R



- Ross Ihaka and Robert Gentleman at the University of Auckland
- An experimental statistical environment
- Scheme interpreter with S-like syntax
 - Replaced scalar type with vector-based types of S
 - Added lazy evaluation of function arguments
- Announced to *s-news* mailing list in August 1993.

International Agency for Research on Cancer
World Health Organization

Pre-history

History

Present

Future?

Packages

- Comprehensive R Archive Network (CRAN) started in 1997
 - Quality assurance tools built into R
 - Increasingly demanding with each new R release
- Recommended packages distributed with R
 - Third-party packages included with R distribution
 - Provide more complete functionality for the R environment
 - Starting with release 1.3.0 (completely integrated in 1.6.0)

International Agency for Research on Cancer
World Health Organization

Pre-history

History

Present

Future?

A free software project

- June 1995. Martin Maechler (ETH, Zurich) persuades Ross and Robert to release R under GNU Public License (GPL)
- March 1996. Mailing list *r-testers* mailing list
 - Later split into three *r-announce*, *r-help*, and *r-devel*.
- Mid 1997. Creation of *core team* with access to central repository (CVS)
 - Doug Bates, Peter Dalgaard, Robert Gentleman, Kurt Hornik, Ross Ihaka, Friedrich Leisch, Thomas Lumley, Martin Maechler, Paul Murrell, Heiner Schwarte, Luke Tierney
- 1997. Adopted by the GNU Project as "GNU S".

International Agency for Research on Cancer
World Health Organization


Pre-history

History

Present

Future?

Growth of CRAN



Source: Dataset CRANpackages in package Ecdat

International Agency for Research on Cancer
World Health Organization

Pre-history

History

Present

Future?

The draw of S

"Early on, the decision was made to use S-like syntax. Once that decision was made, the move toward being more and more like S has been irresistible"
– Ross Ihaka, *R: Past and Future History (Interface '98)*

R 1.0.0, a complete and stable implementation of S version 3, was released in 2000.

International Agency for Research on Cancer
World Health Organization

Pre-history

History

Present

Future?

The present

The current era is characterized by

- A mature R community
- Large penetration of R in the commercial world ("data science", "analytics", "big data")
- Increasing interest in the R language from computer scientists.

International Agency for Research on Cancer
World Health Organization

Pre-historyHistoryPresentFuture?

Community

- UseR! Annual conference
 - Alternating between Europe and N. America
- R Journal.
 - Journal of record, peer-reviewed articles, indexed
 - Also Journal of Statistical Software (JSS) has many articles dedicated to R packages.
- Migration to social media
 - Stack Exchange/Overflow, Github, Twitter (#rstats)

International Agency for Research on Cancer

World Health Organization

Pre-historyHistoryPresentFuture?

Validation and Reliability

- *R: Regulatory Compliance and Validation Issues* guidance document by The R Foundation
- ValidR by Mango Solutions
- MRAN, a time-stamped version of CRAN
 - Allows analysis to be re-run with exactly the same package versions at a later date.
 - Used by Revolution R Open

International Agency for Research on Cancer

World Health Organization

Pre-historyHistoryPresentFuture?

Much important R infrastructure is now in package space

Downloads Jan-May 2015 (thousands)

Source: www.kdnuggets.com/2015/06/top-20-r-packages.html

International Agency for Research on Cancer

World Health Organization

Pre-historyHistoryPresentFuture?

Attack of the Clones (and forks)

Name	Implementation	Commercial sponsor	Open source
pqR	C fork		Yes
CXXR	C++ fork	Google	Yes
ORBIT	C fork	Huawei	Yes
Renjin	Java	BeDataDriven	Yes
FastR	Java (Truffle/Graal)	Oracle	Yes
Riposte	C++	Tableau Research	Yes
TERR	C++	TIBCO	No

A number of projects have looked improving the efficiency of R, either by forking the original codebase or by re-implementing R.

International Agency for Research on Cancer

World Health Organization

Pre-historyHistoryPresentFuture?

The tidyverse

- Many of the popular packages on CRAN were written by Hadley Wickham.
- These packages became known as the “hadleyverse” until Hadley himself rebranded them the “tidyverse” (www.tidyverse.org).
- All packages in the tidyverse have a common design philosophy and work together. Common features are:
 - Non-standard evaluation rules for function calls.
 - Use of the pipe operator %>% to pass data transparently from one function call to another.
- The CRAN meta-package tidyverse installs all of these packages.

International Agency for Research on Cancer

World Health Organization

Pre-historyHistoryPresentFuture?

The R Foundation for Statistical Computing

A non-profit organization working in the public interest, founded in 2002 in order to:

- Provide support for the R project and other innovations in statistical computing.
- Provide a reference point for individuals, institutions or commercial enterprises that want to support or interact with the R development community.
- Hold and administer the copyright of R software and documentation (This never happened)

International Agency for Research on Cancer

World Health Organization

Pre-historyHistoryPresentFuture?

Commercial R

Several commercial organizations provide commercial versions of R including support, consulting, ...

- Revolution Computing, later Revolution Analytics (2007–2014), purchased by Microsoft.
- RStudio (2010–)
- Mango Solution (2002–)

International Agency for Research on Cancer

World Health Organization

Pre-historyHistoryPresentFuture?

The R Consortium

In 2015, a group of organizations created a consortium to support the R ecosystem:

R Foundation A statutory member of The R Consortium

Platinum members IBM, Microsoft, RStudio

Gold members TIBCO

Silver members Alteryx, Avant, Google, Hewlett Packard Enterprise, Ketchum Trading LLC, Mango Solutions, Oracle, ProCogia

International Agency for Research on Cancer

World Health Organization

Pre-history History Present Future?

The Future

"Prediction is very difficult, especially about the future"
– variously attributed to Niels Bohr, Piet Hein, Yogi Bera

International Agency for Research on Cancer
World Health Organization

Pre-history History Present Future?

Back to the Future

Ross Ihaka and Duncan Temple Lang propose a new language built on top of common lisp with:

- Scalar types
- Type hinting
- Call-by-reference semantics
- Use of multi-cores and parallelism
- More strict license to protect work donated to the commons

International Agency for Research on Cancer
World Health Organization

Pre-history History Present Future?

Trends

We cannot make predictions, but some long-term trends are very visible:

- Average age of R Core Team?
- Younger R developers more closely associated with industry than academia
- R Consortium provides mechanism for substantial investment in R infrastructure

International Agency for Research on Cancer
World Health Organization

Pre-history History Present Future?

Julia (www.julialang.org)

"In Julia, I can build a package that achieves good performance without the need to interface to code written in C, C++ or Fortran – in the sense that my package doesn't need to require compilation of code outside that provided by the language itself."

It is not surprising that the design of R is starting to show its age. Although R has only been around for 15-18 years, its syntax and much of the semantics are based on the design of "S3" which is 25-30 years old"

– Doug Bates, message to R-SIG-mixed-models list, December 9 2013

International Agency for Research on Cancer
World Health Organization

Pre-history History Present Future?

R language versus R implementation

- R has no formal specification
- R language is defined by its implementation ("GNU R")
- Long-term future of R may depend on formal specification of the language, rather than current implementation.

International Agency for Research on Cancer
World Health Organization

Pre-history History Present Future?

Resources

- Chambers J, Stages in the Evolution of S
- Becker, R, A Brief History of S
- Chambers R, Evolution of the S language
- Ihaka, R and Gentleman R, R: A language for Data Analysis and Graphics, *J Comp Graph Stat*, **5**, 299–314, 1996.
- Ihaka, R, R: Past and Future History, Interface 98.
- Ihaka, R, Temple Lang, D, Back to the Future: Lisp as a Base for a Statistical Computing System
- Fox, J, Aspects of the Social Organization and Trajectory of the R Project, *R Journal*, Vol 1/2, 5–13, 2009.

International Agency for Research on Cancer
World Health Organization

Pre-history History Present Future?

Simply start over and build something better

The `x` in this function is randomly local or global

```
f = function() {
  if (runif(1) > .5)
    x = 10
  x
}
```

"In the light of this, I've come to the conclusion that rather than "fixing" R, it would be better and much more productive to simply start over and build something better" – Ross Ihaka, Christian Robert's blog, September 13, 2010

International Agency for Research on Cancer
World Health Organization

Basics The workspace

R: language and basic data management

Krista Fischer

Statistical Practice in Epidemiology, Tartu, 2017
(initial slides by P. Dalgaard)

1 / 23

Language

- ▶ R is a programming language – also on the command line
- ▶ (This means that there are *syntax rules*)
- ▶ Print an object by typing its name
- ▶ Evaluate an expression by entering it on the command line
- ▶ Call a function, giving the arguments in parentheses – possibly empty
- ▶ Notice `objects` vs. `objects()`

2 / 23

Function calls

Lots of things you do with R involve calling functions. For instance

```
mean(x, na.rm=TRUE)
```

The important parts of this are

- ▶ The **name** of the function
- ▶ **Arguments**: input to the function
- ▶ Sometimes, we have **named arguments**

5 / 23

Objects

- ▶ The simplest object type is *vector*
- ▶ Modes: numeric, integer, character, generic (list)
- ▶ Operations are vectorized: you can add entire vectors with `a + b`
- ▶ Recycling of objects: If the lengths don't match, the shorter vector is reused

3 / 23

Function arguments

Examples:

```
rmnorm(10, mean=m, sd=s)
hist(x, main="My histogram")
mean(log(x + 1))
```

Items which may appear as arguments:

- ▶ **Names** of an R objects
- ▶ Explicit **constants**
- ▶ **Return values** from another function call or expression
- ▶ Some arguments have their *default values*.
- ▶ Use `help(function)` or `args(function)` to see the arguments (and their order and default values) that can be given to any function.
- ▶ Keyword matching: `t.test(x ~ g, mu=2, alternative="less")`
- ▶ Partial matching: `t.test(x ~ g, mu=2, alt="l")`

6 / 23

Demo 1

```
x <- round(rnorm(10,mean=20,sd=5)) # simulate data
x
mean(x)
m <- mean(x)
m
x - m # notice recycling
(x - m)^2
sum((x - m)^2)
sqrt(sum((x - m)^2)/9)
sd(x)
```

3 / 23

Creating simple functions

```
logit <- function(p) log(p/(1-p))
logit(0.5)
simpsum <- function(x, dec=5)
  # produces mean and SD of a variable
  # default value for dec is 5
round(c(mean=mean(x), sd=sd(x)), dec)
x<-rnorm(100)
simpsum(x)
simpsum(x,2)
```

7 / 23

R expressions

```
x <- rnorm(10, mean=20, sd=5)
m <- mean(x)
sum((x - m)^2)
```

- ▶ Object **names**
- ▶ Explicit **constants**
- ▶ Arithmetic **operators**
- ▶ **Function calls**
- ▶ **Assignment** of results to names

4 / 23

Indexing

- ▶ R has several useful indexing mechanisms:
- ▶ `a[5]` single element
- ▶ `a[5:7]` several elements
- ▶ `a[-6]` all except the 6th
- ▶ `a[b>200]` logical index

8 / 23

Lists

- ▶ Lists are vectors where the elements can have different types
- ▶ Functions often return lists
- ▶ `lst <- list(A=rnorm(5), B="hello")`
- ▶ Special indexing:
- ▶ `lst$A`
- ▶ `lst[[1]]` first element (NB: double brackets)

9/23

Data manipulation and `with`

To create a new variable in the data frame, you could use:

```
students$bmi <-
with(students, weight/(height/100)^2)
```

...while

```
with(students, bmi <- weight/(height/100)^2)
```

uses variables `weight` and `height` in the data frame `students2001_05`, but creates the variable `bmi` in the global environment (not in the data frame).

13/23

Classes, generic functions

- ▶ R objects have *classes*
- ▶ Functions can behave differently depending on the class of an object
- ▶ E.g. `summary(x)` or `print(x)` does different things if `x` is numeric, a factor, or a linear model fit

10/23

Constructors

- ▶ We have (briefly) seen the `c` and `list` functions
- ▶ For matrices and arrays, use the (surprise) `matrix` and `array` functions. `data.frame` for data frames.
- ▶ Notice the naming forms `c(boys=1.2, girls=1.1)`
- ▶ You can extract and set names with `names(x)`; for matrices and data frames also `colnames(x)` and `rownames(x)`;
- ▶ It is also fairly common to construct a matrix from its columns using `cbind`, whereas joining two matrices with equal no of columns (with the same column names) can be done using `rbind`.

14/23

The workspace

- ▶ The *global environment* contains R objects created on the command line.
- ▶ There is an additional *search path* of loaded packages and attached data frames.
- ▶ When you request an object by name, R looks first in the global environment, and if it doesn't find it there, it continues along the search path.
- ▶ The search path is maintained by `library()`, `attach()`, and `detach()`
- ▶ Notice that objects in the global environment may mask objects in packages and attached data frames

11/23

Conditional assignment: `ifelse`

- ▶ Syntax: `ifelse(expr, A, B)` where `expr` is a logical expression, takes value A, if expression is TRUE and value B if FALSE
- ▶ Examples:

```
x<-c(1,2,7,1,NA)
ifelse(x<3,1,2)
ifelse(is.na(x),0,x)
ifelse(is.na(x),0,ifelse(x<3,1,2))
y<-c(3,6,1,7,8)
z<-c(0,0,0,1,1)
ifelse(z==0,x,y)
```

14/23

How to access variables in the data frame?

Different ways to tell R to use variable X from data frame D:

- ▶ Use the `dataframe$variable` notation
`summary(D$X)`
- ▶ Use the `with` function
`with(D, summary(X))`
- ▶ Use the `data` argument (works for some functions only)
`lm(Y~X, data=D)`
- ▶ Attach the dataframe – **DISCOURAGED!**
(seems a convenient solution, but can actually make things more complicated, as it creates a temporary copy of the dataset)
`attach(D)`
`summary(X)`
`detach()`

12/23

Factors

- ▶ Factors are used to describe groupings (the term originates from *factorial designs*)
- ▶ Basically, these are just integer codes plus a set of names for the *levels*
- ▶ They have class "`factor`" making them (a) print nicely and (b) maintain consistency
- ▶ A factor can also be *ordered* (class "`ordered`"), signifying that there is a natural sort order on the levels
- ▶ In model specifications, factors play a fundamental role by indicating that a variable should be treated as a classification rather than as a quantitative variable (similar to a CLASS statement in SAS)

15/23

The `factor` Function

- ▶ This is typically used when `read.table` gets it wrong
- ▶ E.g. group codes read as numeric
- ▶ Or read as factors, but with levels in the wrong order (e.g. `c("rare", "medium", "well-done")` sorted alphabetically.)
- ▶ Notice that there is a slightly confusing use of `levels` and `labels` arguments.
- ▶ `levels` are the value codes *on input*
- ▶ `labels` are the value codes *on output* (and become the levels of the resulting factor)

16 / 23

Working with Dates

- ▶ Dates are usually read as character or factor variables
- ▶ Use the `as.Date` function to convert them to objects of class "Date"
- ▶ If data are not in the default format (YYYY-MM-DD) you need to supply a format specification


```
> as.Date("11/3-1959", format="%d/%m-%Y")
[1] "1959-03-11"
```
- ▶ You can calculate differences between Date objects. The result is an object of class "difftime". To get the number of days between two dates, use


```
> as.numeric(as.Date("2017-6-1") -
              as.Date("1959-3-11"), "days")
[1] 17607
```

17 / 23

Demo 2

```
aq <- airquality
aq$Month
aq$Month <- factor(aq$Month, levels=5:9,
                  labels=month.name[5:9])

aq$Month
table(aq$Month)

aq <- airquality
aq$Month <- factor(aq$Month, levels=1:12,
                  labels=month.name)
table(aq$Month)
```

(Note: there can be factor levels with 0 observations in the dataset)

16 / 23

Basic graphics

The `plot()` function is a generic function, producing different plots for different types of arguments. For instance, `plot(x)` produces:

- ▶ a plot of observation index against the observations, when `x` is a numeric variable
- ▶ a bar plot of category frequencies, when `x` is a factor variable
- ▶ a time series plot (interconnected observations) when `x` is a time series
- ▶ a set of diagnostic plots, when `x` is a fitted regression model
- ▶ ...

18 / 23

The `cut` Function

- ▶ The `cut` function converts a numerical variable into groups according to a set of break points
- ▶ Notice that the number of breaks is one more than the number of intervals
- ▶ Notice also that the intervals are left-open, right-closed by default (`right=FALSE` changes that)
- ▶ ... and that the lowest endpoint is *not* included by default (set `include.lowest=TRUE` if it bothers you)

17 / 23

Basic graphics

Similarly, the `plot(x, y)` produces:

- ▶ a scatter plot, when `x` is a numeric variable
- ▶ a bar plot of category frequencies, when `x` is a factor variable

19 / 23

Demo 3

```
st<-students
range(st$age)
st$agegr <- cut(st$age, c(18,seq(20,45,5)),
               right=FALSE, include.lowest=TRUE)
table(st$agegr)
st$agegr <- cut(st$age, c(18,20,22,25,41),
               right=FALSE, include.lowest=TRUE)
table(st$agegr)
```

17 / 23

Basic graphics

Examples:

```
x <- c(0,1,2,1,2,2,1,1,3,3)
plot(x)
plot(factor(x))
plot(ts(x))      # ts() defines x as time series
y <- c(0,1,3,1,2,1,0,1,4,3)
plot(x,y)
plot(factor(x),y)
```

20 / 23

Basic graphics

More simple plots:

- `hist(x)` produces a histogram
- `barplot(x)` produces a bar plot (useful when `x` contains counts – often one uses `barplot(table(x))`)
- `boxplot(y ~ x)` produces a box plot of `y` by levels of a (factor) variable `x`.

21 / 23

Points to be covered

1. Incidence rates, rate ratios and rate differences from *follow-up studies* can be computed by fitting *Poisson regression models*.
2. Odds ratios can be computed from binary data by fitting *Logistic regression models*.
3. Odds-ratios can be estimated from case-control studies.
4. Both models are special instances of *Generalized linear models*.
5. There are various ways to do these tasks in R.

2 / 26

Simple simulation

Simulation in R is very easy. It is often useful to simulate artificial data to see whether a method works or how a distribution looks like.


Example 1: continuous probability distributions

```
par(mfrow=c(2,2))
x1 <- runif(100) # Uniform [0,1]
hist(x1)
x2 <- rnorm(100) # Standard Normal
hist(x2)
x3 <- rnorm(100, mean=20, sd=6) # N(20,6)
hist(x3)
x4 <- rbeta(100,0.1,0.1) # Beta
hist(x4)
hist(x2^2)
hist(x4*x3)
```

22 / 23

The Estonian Biobank cohort: survival among the elderly

Follow-up of 60 random individuals aged 75-103 at recruitment, until death (●) or censoring (○) in April 2014 (linkage with the Estonian Causes of Death Registry).



3 / 26

Simple simulation

Example 2: Discrete distributions and a simple model

```
x5 <- rpois(100,3) # Poisson, lambda=3
table(x5)
barplot(table(x5))
x6 <- rbinom(100,1,0.3) # Bin(1,0.3)
#(Bernoulli, p=0.3)


table(x6)
x7<-x6+rnorm(100)
tapply(x7,x6,mean) # are the means close
# to what is simulated?

boxplot(x7~x6)
summary(lm(x7~x6))
```

23 / 23

The Estonian Biobank cohort: survival among the elderly

Follow-up time for 60 random individuals aged 75-103 at recruitment (time-scale: time in study).



4 / 26

Statistical Practice in Epidemiology 2017

Poisson regression for cohort studies
Logistic regression for binary data

Janne Pitkaniemi
(EL)

1 / 26

Events, dates and risk time

- Mortality as the outcome:
 - d: indicator for **status** at exit:
 - 1: death observed
 - 0: censored alive
- Dates:
 - doe = date of **E**ntry to follow-up,
 - dox = date of **e**Xit, end of follow-up.
- Follow-up time (years) computed as:

$$y = (\text{dox} - \text{doe}) / 365.25$$

5 / 26

Crude overall rate computed in two ways

Total no. cases, person-years & rate (/1000 y):

```
> D <- sum( d ); Y <- sum( y ); R <- D/(Y/1000)
> round( c(D=D, Y=Y, R=R), 2)
      D      Y      R
884.00 11678.24  75.70
```

Poisson regression model with only intercept ("1").

```
> m1 <- glm( d ~ 1, family=poisson, offset=log(y) )
> coef(m1)
(Intercept)
-2.581025
```

```
> exp( coef(m1) ) * 1000
(Intercept)
75.69636
```

Why do we get the same results?

6 / 26

Comparing rates: thorotrast vs. control

Tabulating cases, person-years & rates by group

```
> stat.table( contrast,
+             list( N = count(),
+                 D = sum(d),
+                 Y = sum(y),
+                 rate = ratio(d,y,1000) ) )
```

contrast	N	D	Y	rate
ctrl	1236	797.00	30517.56	26.12
thor	807	748.00	19243.85	38.87

Rate ratio, $RR = 38.89/26.12 = 1.49$,
 Std. error of log-RR, $SE = \sqrt{1/748 + 1/797} = 0.051$,
 Error factor, $EF = \exp(1.96 \times 0.051) = 1.105$,
 95% confidence interval for RR:
 $(1.49/1.105, 1.49 \times 1.105) = (1.35, 1.64)$.

10 / 26

Constant hazard — Poisson model

Let $T \sim \exp(\lambda)$, then $f(y; \lambda) = \lambda e^{-\lambda y} I(y > 0)$

Constant rate: $\lambda(y) = \frac{f(y; \lambda)}{S(y; \lambda)} = \lambda$

Observed data $\{(y_i, \delta_i); i = 1, \dots, n\}$.

The likelihood $L(\lambda) = \prod_{i=1}^n \lambda^{\delta_i} e^{-\lambda y_i}$ and

$\log(L) = \sum_{i=1}^n [\delta_i \log(\lambda) - \lambda y_i]$

Solving the score equations: $\frac{\partial \log L(\lambda)}{\partial \lambda} = \sum [\frac{\delta_i}{\lambda} - y_i]$
 $= \frac{D}{\lambda} - Y = 0$ and $D - \lambda Y = 0$

→ **maximum likelihood estimator (MLE)** of λ :

$$\hat{\lambda} = \frac{D}{Y} = \frac{\text{number of cases}}{\text{total person-time}} = \text{empirical rate!}$$

7 / 26

Rate ratio estimation with Poisson regression

- ▶ Include contrast as the explanatory variable (factor).
- ▶ Insert person years in units that you want rates in

```
> m2 <- glm( d ~ contrast, offset=log(y/1000),
+           family = poisson )
> round( summary(m2)$coef, 4)[, 1:2]
```

	Estimate	Std. Error
(Intercept)	3.2626	0.0354
contrast thor	0.3977	0.0509

- ▶ Rate ratio and CI?
Call function `ci.exp()` in Epi

```
> round( ci.exp( m2 ), 3 )
```

	exp(Est.)	2.5%	97.5%
(Intercept)	26.116	24.364	27.994
contrast thor	1.488	1.347	1.644

11 / 26

offset term — Poisson model

Previous model without offset: Intercept 6.784=log(884)

We should use an offset if we suspect that the underlying **population sizes (person-years) differ** for each of the observed counts – For example varying person-years by treatment group, sex, age,...

We need a term in the model that "scales" the likelihood, but does not depend on model parameters (include a **term with reg. coef. fixed to 1**) – offset term is $\log(y)$

$$\log\left(\frac{\mu}{y}\right) = \beta_0 + \beta_1 x_1$$

$$\log(\mu) = 1 \times \log(y) + \beta_0 + \beta_1 x_1$$

8 / 26

Rates in groups with Poisson regression

- ▶ Include contrast as the explanatory variable (factor).
- ▶ Remove the intercept (-1)
- ▶ Insert person-years in units that you want rates in

```
> m3 <- glm( d ~ contrast - 1,
+           offset=log(y/1000),
+           family = poisson )
> round( summary(m3)$coef, 4)[, 1:2]
```

	Estimate	Std. Error
contrast ctrl	3.2626	0.0354
contrast thor	3.6602	0.0366

```
> round( ci.exp( m3 ), 3 )
```

	exp(Est.)	2.5%	97.5%
contrast ctrl	26.116	24.364	27.994
contrast thor	38.870	36.181	41.757

12 / 26

Comparing rates: The Thorotrast Study

- ▶ Cohort of seriously ill patients in Denmark on whom angiography of brain was performed.
- ▶ Exposure: contrast medium used in angiography,
 1. thor = thorotrast (with ^{232}Th), used 1935-50
 2. ctrl = other medium (?), used 1946-63
- ▶ Outcome of interest: death

doe = date of **E**ntry to follow-up,
 dox = date of **e**Xit, end of follow-up.

- ▶ data(thoro) in the Epi package.

9 / 26

Rates in groups with Poisson regression

- ▶ You can have it all in one go:

```
> CM <- rbind( c(1,0), c(0,1), c(-1,1) )
> rownames(CM) <- c("Ctrl", "Thoro", "Th vs. Ct")
> colnames(CM) <- names( coef(m3) )
> CM
```

	contrast	ctrl	contrast	thor
Ctrl		1		0
Thoro		0		1
Th vs. Ct		-1		1

```
> round( ci.exp( m3, ctr.mat=CM ), 3 )
```

	exp(Est.)	2.5%	97.5%
Ctrl	26.116	24.364	27.994
Thoro	38.870	36.181	41.757
Th vs. Ct	1.488	1.347	1.644

13 / 26

Rate ratio estimation with Poisson regression

► Response may also be specified as individual *rates*:
d/y
weights= instead of offset= are needed.

```
> m4<-glm( d/(y/1000)~contrast, weights=y/1000,
+         family=poisson)
> round( ci.exp(m4), 3 )
```

	exp(Est.)	2.5%	97.5%
(Intercept)	26.116	24.365	27.994
contrast thor	1.488	1.347	1.644

14 / 26

The difference between the probabilities is the fraction of the patients that benefit from the treatment: $p_{Dal} - p_{Pl}$

```
> dlt <- rbind( c(29,14), c(20,22) )
> colnames( dlt ) <- c("Better","Worse")
> rownames( dlt ) <- c("Dal","Pl")
> twoby2( dlt )
```

2 by 2 table analysis:
/.../

	Better	Worse	P(Better)	95% conf. interval
Dal	29	14	0.6744	0.5226 0.7967
Pl	20	22	0.4762	0.3316 0.6249

95% conf. interval

	Relative Risk:	1.4163	0.9694	2.0692
Sample Odds Ratio:	2.2786	0.9456	5.4907	
Conditional MLE Odds Ratio:	2.2560	0.8675	6.0405	
Probability difference:	0.1982	-0.0110	0.3850	

Exact P-value: 0.0808
Asymptotic P-value: 0.0665

18 / 26

Rate difference estimation with Poisson regression

► The approach with d/y enables additive rate models too:

```
> m5 <- glm( d/(y/1000) ~ contrast, weights=y/1000,
+         family=poisson(link="identity") )
> round( ci.exp(m5,Exp=F), 3 )
```

	Estimate	2.5%	97.5%
(Intercept)	26.116	24.303	27.929
contrast thor	12.753	9.430	16.077

15 / 26

Logistic regression for binary data

For grouped binary data, the response is a two-column matrix with columns (successes, failures).

```
> trt <- factor(c("Dal","Pl"))
> b1 <- glm( dlt ~ trt, family=binomial )
> ci.exp( b1 )
```

	exp(Est.)	2.5%	97.5%
(Intercept)	2.0714286	1.0945983	3.919992
trtPl	0.4388715	0.1821255	1.057557

Oops! Dalterapin has become the reference group; we want Placebo to be the reference...

19 / 26

Rates difference

► As before you can have it all:

```
> m6 <- glm( d/(y/1000) ~ contrast -1,
+         family = poisson(link="identity"),
+         weights = y/1000)
> round(ci.exp(m6, ctr.mat=CM, Exp=F ), 3)
```

	Estimate	2.5%	97.5%
Ctrl	26.116	24.303	27.929
Thoro	38.870	36.084	41.655
Th vs. Ct	12.753	9.430	16.077

```
> round( ci.exp( m3, ctr.mat=CM), 3 )
```

	exp(Est.)	2.5%	97.5%
Ctrl	26.116	24.364	27.994
Thoro	38.870	36.181	41.757
Th vs. Ct	1.488	1.347	1.644

16 / 26

Logistic regression for binary data

```
> trt <- relevel( trt, 2 )
> b1 <- glm( dlt ~ trt, family=binomial )
> round( ci.exp( b1 ), 4 )
```

	exp(Est.)	2.5%	97.5%
(Intercept)	0.9091	0.4962	1.6657
trtDal	2.2786	0.9456	5.4907

The default parameters in logistic regression are **odds** (the intercept: $20/22 = 0.9090$) and the **odds-ratio** ($((29/14)/(20/22) = 2.28)$).

20 / 26

Binary data: Treatment success Y/N

85 diabetes-patients with foot-wounds:

- Dalterapin (Dal)
- Placebo (Pl)

		Treatment group	
		Dalterapin	Placebo
Outcome:	Better	29	20
	Worse	14	22
		43	42

$$\hat{p}_{Dal} = \frac{29}{43} = 67\% \quad \hat{p}_{Pl} = \frac{20}{42} = 47\%$$

17 / 26

Case-control study: Food-poisoning outbreak

- An outbreak of acute gastrointestinal illness (AGI) occurred in a psychiatric hospital in Dublin in 1996.
- Out of all 423 patients and staff members, 65 were affected during 27 to 31 August, 1996.
- 65 cases and 62 randomly selected control subjects were interviewed.
- Exposure of interest: chocolate mousse cake.
- 47 cases and 5 controls reported having eaten the cake.

Ref: <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=188> – here original numbers somewhat modified.

21 / 26

Outbreak: crude summary of results

Distribution of exposure to chocolate mousse cake

Group	Exposed	Unexposed	Total
Cases	$D_1 = 47$ (72%)	$D_0 = 18$ (28%)	$D = 65$ (100%)
Controls	$C_1 = 5$ (8%)	$C_0 = 57$ (92%)	$C = 62$ (100%)
Case/Ctr ratio	$47/5 = 9.4$	$18/57 = 0.32$	

- ▶ The absolute size of case/control ratio depends on how many cases and controls we selected.
- ▶ The **ratio** of the case/control ratio says something about the exposure effect.

22 / 26

Conclusion: What did we learn?

- ▶ Poisson regression models.
- ▶ In Poisson models the response can be either:
 - ▶ case indicator d with $\text{offset} = \log(y)$, or
 - ▶ rate d/y with $\text{weights} = y$.
- ▶ Both may be fitted on either grouped data, or individual records.
- ▶ Binary data can be modeled with odds.
- ▶ Case-control studies:
 - Odds-ratios can be computed by logistic regression models, but **Intercept** from model is **meaningless**.

26 / 26

p probability to be exposed, π probability of failure, 0.99 and 0.17 sampling (selection) fractions of cases and controls

$$\text{Odds of disease} = \frac{P\{\text{Case given inclusion}\}}{P\{\text{Control given inclusion}\}}$$

$$\omega_1 = \frac{p \times \pi_1 \times 0.99}{p \times (1 - \pi_1) \times 0.17} = \frac{0.99}{0.17} \times \frac{\pi_1}{1 - \pi_1}$$

$$\omega_0 = \frac{(1 - p) \times \pi_0 \times 0.99}{(1 - p) \times (1 - \pi_0) \times 0.17} = \frac{0.99}{0.17} \times \frac{\pi_0}{1 - \pi_0}$$

$$\text{OR} = \frac{\omega_1}{\omega_0} = \frac{\pi_1}{1 - \pi_1} \bigg/ \frac{\pi_0}{1 - \pi_0} = \text{OR}(\text{disease})_{\text{population}}$$

23 / 26

Linear and generalized linear models

Friday 2 June, 14:30-15:00

Esa Läärä

Statistical Practice in Epidemiology with R
1 to 6 June, 2017
University of Tartu, Estonia

Logistic regression in case-control studies

- ▶ Model for disease occurrence in the population:

$$\text{logit}(P\{\text{case}\}) = \ln \left[\frac{p}{1 - p} \right] = \beta_0 + \beta_1 x_1 + \beta_2 x_2 = \eta$$

- ▶ Sampling fractions:

$$\begin{aligned} P\{\text{inclusion in study}|\text{control}\} &= s_{\text{ctr}} \\ P\{\text{inclusion in study}|\text{case}\} &= s_{\text{cas}} \end{aligned}$$

- ▶ Model for observed case-control data:

$$\begin{aligned} \ln[\text{odds (case — incl.)}] &= \ln \left[\frac{p}{1 - p} \right] + \ln \left[\frac{s_{\text{cas}}}{s_{\text{ctr}}} \right] \\ &= \left(\ln \left[\frac{s_{\text{cas}}}{s_{\text{ctr}}} \right] + \beta_0 \right) + \beta_1 x_1 + \beta_2 x_2 \end{aligned}$$

24 / 26

Outline

- ▶ Simple linear regression.
- ▶ Fitting a model and extracting results.
- ▶ Predictions and diagnostics.
- ▶ Categorical factors and contrast matrices.
- ▶ Main effects and interactions.
- ▶ Generalized linear models.
- ▶ Modelling curved effects.

Linear and generalized linear models

1 / 22

Logistic regression in case-control studies

Analysis of $P\{\text{case} \text{ — inclusion}\}$ — i.e. binary observations:

$$Y = \begin{cases} 1 & \sim \text{case} \\ 0 & \sim \text{control} \end{cases}$$

$$\ln[\text{odds (case — incl.)}] = \left(\ln \left[\frac{s_{\text{cas}}}{s_{\text{ctr}}} \right] + \beta_0 \right) + \beta_1 x_1 + \beta_2 x_2$$

- ▶ Effect of covariates is estimated correctly.
- ▶ Intercept is meaningless — depends on s_{cas} and s_{ctr} that are often unknown.

25 / 26

Variables in generalized linear models

- ▶ The **outcome** or **response** variable must be numeric.
- ▶ Main types of response variables are
 - Metric or continuous (a measurement with units)
 - Binary (two values coded 0/1)
 - Failure (does the subject fail at end of follow-up)
 - Count (aggregated failure data, number of cases)
- ▶ **Explanatory** variables or **regressors** can be
 - Numeric or quantitative variables
 - Categorical factors, represented by class indicators or contrast matrices.

Linear and generalized linear models

2 / 22

The births data in Epi

id: Identity number for mother and baby.
 bweight: Birth weight of baby.
 lowbw: Indicator for birth weight less than 2500 g.
 gestwks: Gestation period in weeks.
 preterm: Indicator for gestation period less than 37 weeks.
 matage: Maternal age.
 hyp: Indicator for maternal hypertension (0 = no, 1 = yes).
 sex: Sex of baby (1 = male, 2 = female).

Declaring and transforming some variables as factors:

```
> library(Epi) ; data(births)
> births <- transform(births,
+   hyp = factor(hyp, labels=c("N", "H")),
+   sex = factor(sex, labels=c("M", "F")),
+   gest4 = cut(gestwks, breaks=c(20, 35, 37, 39, 45), right=FALSE))
> births <- subset(births, !is.na(gestwks))
```

Linear and generalized linear models

3 / 22

Other extractor functions, for example


- ▶ fitted(m), resid(m), vcov(m), ...
- ▶ predict(m, newdata = ..., interval=...)
 - Predicted responses for desired combinations of new values of the regressors – newdata
 - Argument interval specifies whether **confidence** intervals for the *mean* response or **prediction** intervals for *individual* responses are returned.
- ▶ plot(m) – produces various diagnostic plots based on residuals (raw or standardized)

Many of these are special **methods** for certain **generic functions**, aimed at acting on objects of class "lm".

Linear and generalized linear models

7 / 22

Birth weight and gestational age




```
> with(births, plot(bweight ~ gestwks, xlim = c(24,45), pch = 1,
+   xlab = "Gestational age (wk)", ylab = "Birth weight (g)"))
```

Linear and generalized linear models

4 / 22

Fitted values, confidence & prediction intervals



```
> nd <- data.frame( gestwks = seq(24, 45, by = 0.25) )
> pr.c1 <- predict( m, newdata=nd, interval="conf" )
> pr.p1 <- predict( m, newdata=nd, interval="pred" )
> with(births, plot(bweight ~ gestwks, xlim = c(24,45), cex.axis=1.5, cex.lab = 1.5,
+   matlines( nd$gestwks, pr.c1, lty=1, lwd=c(3,2,2), col=c(red,blue,blue))
+   matlines( nd$gestwks, pr.p1, lty=1, lwd=c(3,2,2), col=c(red,green,green))
```

Linear and generalized linear models

8 / 22

Metric response, numeric explanatory variable

Roughly linear relationship btw bweight and gestwks

→ Simple **linear regression model** fitted.

- ```
> m <- lm(bweight ~ gestwks, data=births)
```
- ▶ `lm()` is the function that fits linear regression models, assuming **Gaussian** distribution for **error** terms.
  - ▶ `bweight ~ gestwks` is the **model formula**
  - ▶ `m` is a **model object** belonging to **class "lm"**.

> coef(m) – Printing the estimated regression coefficients


```
(Intercept) gestwks
 -4489.1 197.0
```

Interpretation of **intercept** and **slope**?

Linear and generalized linear models

5 / 22

## A couple of diagnostic plots



- ```
> par(mfrow=c(1,2))
> plot(m, 1:2, cex.lab = 1.5, cex.axis=1.5, cex.caption=1.5)
```
- ▶ Some deviation from linearity?
 - ▶ Reasonable agreement with Gaussian error assumption?

Linear and generalized linear models

9 / 22

Model object and extractor functions

Model object = **list** of different elements, each being separately accessible. – See `str(m)` for the full list.

Functions that extract results from the fitted model object

- ▶ `summary(m)` – lots of output
- ▶ `coef(m)` – beta-hats only (see above)
- ▶ `ci.lin(m)[,c(1,5,6)]` – $\hat{\beta}_j$ s plus confidence limits

	Estimate	2.5%	97.5%
(Intercept)	-4489.1	-5157.3	-3821.0
gestwks	197.0	179.7	214.2

 This function is in Epi package
- ▶ `anova(m)` – Analysis of Variance Table

Linear and generalized linear models

6 / 22

Factor as an explanatory variable

- ▶ How bweight depends on maternal hypertension?

```
> mh <- lm( bweight ~ hyp, data=births)
```

```
Estimate 2.5% 97.5%
(Intercept) 3198.9 3140.2 3257.6
hypH -430.7 -585.4 -275.9
```

- ▶ Removal of intercept → mean bweights by hyp:


```
> mh2 <- lm( bweight ~ -1 + hyp, data = births)
> coef(mh2)
hypN hypH
3198.9 2768.2
```
- ▶ Interpretation: $-430.7 = 2768.2 - 3198.9 =$ difference between level 2 vs. reference level 1 of hyp

Linear and generalized linear models

10 / 22

Additive model with both gestwks and hyp

- Joint effect of hyp and gestwks under additivity is modelled e.g. by updating a simpler model:

```
> mhg <- update(mh, . ~ . + gestwks)
```

	Estimate	2.5%	97.5%
(Intercept)	-4285.0	-4969.7	-3600.3
hypH	-143.7	-259.0	-28.4
gestwks	192.2	174.7	209.8
- The effect of hyp: H vs. N is attenuated (from -430.7 to -143.7).
- This suggests that much of the effect of hypertension on birth weight is mediated through a shorter gestation period among hypertensive mothers.

Linear and generalized linear models

11/ 22

Two factors: additive effects

- Factor X has 3 levels, Z has 2 levels – Model:

$$\mu = \alpha + \beta_1 X_1 + \beta_2 X_2 + \beta_3 X_3 + \gamma_1 Z_1 + \gamma_2 Z_2$$

- X_1 (reference), X_2, X_3 are the indicators for X ,
- Z_1 (reference), Z_2 are the indicators for Z .
- Omitting X_1 and Z_1 the model for mean is:

$$\mu = \alpha + \beta_2 X_2 + \beta_3 X_3 + \gamma_2 Z_2$$

with predicted means μ_{jk} ($j = 1, 2, 3; k = 1, 2$):

	$Z = 1$	$Z = 2$
$X = 1$	$\mu_{11} = \alpha$	$\mu_{11} = \alpha + \gamma_2$
$X = 2$	$\mu_{21} = \alpha + \beta_2$	$\mu_{22} = \alpha + \beta_2 + \gamma_2$
$X = 3$	$\mu_{31} = \alpha + \beta_3$	$\mu_{32} = \alpha + \beta_3 + \gamma_2$

Linear and generalized linear models

15/ 22

Model with interaction of hyp and gestwks

- ```
mhgi <- lm(bweight ~ hyp + gestwks + hyp:gestwks, data = births)
```
- Or with shorter formula: `bweight ~ hyp * gestwks`  

|              | Estimate | 2.5%    | 97.5%   |
|--------------|----------|---------|---------|
| (Intercept)  | -3960.8  | -4758.0 | -3163.6 |
| hypH         | -1332.7  | -2841.0 | 175.7   |
| gestwks      | 183.9    | 163.5   | 204.4   |
| hypH:gestwks | 31.4     | -8.3    | 71.1    |
- Estimated slope: 183.9 g/wk in reference group N and 183.9 + 31.4 = 215.3 g/wk in hypertensive mothers.
- ⇒ For each additional week the difference in mean bweight between H and N group increases by 31.4 g.
- Interpretation of Intercept and “main effect” hypH?

Linear and generalized linear models

12/ 22

## Two factors with interaction

- Effect of  $Z$  differs at different levels of  $X$ :

|         | $Z = 1$                       | $Z = 2$                                                |
|---------|-------------------------------|--------------------------------------------------------|
| $X = 1$ | $\mu_{11} = \alpha$           | $\mu_{12} = \alpha + \gamma_2$                         |
| $X = 2$ | $\mu_{21} = \alpha + \beta_2$ | $\mu_{22} = \alpha + \beta_2 + \gamma_2 + \delta_{22}$ |
| $X = 3$ | $\mu_{31} = \alpha + \beta_3$ | $\mu_{32} = \alpha + \beta_3 + \gamma_2 + \delta_{32}$ |

- How much the effect of  $Z$  (level 2 vs. 1) changes when the level of  $X$  is changed from 1 to 3:  

$$\delta_{32} = (\mu_{32} - \mu_{31}) - (\mu_{12} - \mu_{11})$$

$$= (\mu_{32} - \mu_{12}) - (\mu_{31} - \mu_{11}),$$

= how much the effect of  $X$  (level 3 vs. 1) changes when the level of  $Z$  is changed from 1 to 2.
- See the exercise: interaction of hyp and gest4.

Linear and generalized linear models

16/ 22

## Model with interaction (cont'd)

More interpretable parametrization obtained if `gestwks` is **centered** at some reference value, using e.g. the `insulate` operator `I()` for explicit transformation of an original term.

- ```
mi2 <- lm(bweight ~ hyp*I(gestwks-40), ...)
```


	Estimate	2.5%	97.5%
(Intercept)	3395.6	3347.5	3443.7
hypH	-77.3	-219.8	65.3
I(gestwks - 40)	183.9	163.5	204.4
hypH:I(gestwks - 40)	31.4	-8.3	71.1
- Main effect of hyp = -77.3 is the difference between H and N at `gestwks = 40`.
- Intercept = 3395.6 is the estimated mean bweight at the reference value 40 of `gestwks` in group N.

Linear and generalized linear models

13/ 22

Contrasts in R

- All contrasts can be implemented by supplying a suitable **contrast function** giving the **contrast matrix** e.g:

```
> contr.cum(3)      > contr.sum(3)
1 0 0                1  1  0
2 1 0                2  0  1
3 1 1                3 -1 -1
```

- In model formula factor name `faktori` can be replaced by expression like `C(faktori, contr.cum)`.
- Function `ci.lin()` has an option for calculating CI's for linear functions of the parameters of a fitted model `mall` when supplied by a relevant contrast matrix

```
> ci.lin(mall, ctr.mat = CM)[ , c(1,5,6)]
```

→ No need to specify contrasts in model formula!

Linear and generalized linear models

17/ 22

Factors and contrasts in R

- A categorical explanatory variable or **factor** with L levels will be represented by $L - 1$ linearly independent columns in the **model matrix** of a linear model.
- These columns can be defined in various ways implying alternative **parametrizations** for the effect of the factor.
- Parametrization is defined by given type of **contrasts**.
- Default: **treatment** contrasts, in which 1st class is the **reference**, and regression coefficient β_k for class k is interpreted as $\beta_k = \mu_k - \mu_1$
- Own parametrization may be tailored by function `C()`, with the pertinent **contrast matrix** as argument.
- Or, use `ci.lin(mod, ctr.mat = CM)` after fitting.

Linear and generalized linear models

14/ 22

From linear to generalized linear models

- An alternative way of fitting our 1st Gaussian model:

```
> m <- glm(bweight ~ gestwks, family=gaussian, data=bir)
```
- Function `glm()` fits **generalized linear models** (GLM).
- Requires specification of the
 - family** – i.e. the assumed “error” distribution for Y_i s,
 - link** function – a transformation of the expected Y_i .
- Covers common models for other types of response variables and distributions, too, e.g. **logistic** regression for binary responses and **Poisson** regression for counts.
- Fitting: method of **maximum likelihood**.
- Many extractor functions for a `glm` object similar to those for an `lm` object.

Linear and generalized linear models


18/ 22

More about numeric regressors

What if dependence of Y on X is non-linear?

- ▶ **Categorize** the values of X into a factor.
 - Continuous effects violently discretized by often arbitrary cutpoints. – Inefficient.
- ▶ Fit a low-degree (e.g. 2 to 4) **polynomial** of X .
 - Tail behaviour may be problematic.
- ▶ Use **fractional polynomials**.
 - Invariance problems. Only useful if $X = 0$ is well-defined.
- ▶ Use a **spline** model: smooth function $s(X; \beta)$.
 - More flexible models that act locally.
 - Effect of X reported by graphing $\hat{s}(X; \beta)$ & its CI
 - See Martyn's lecture


Mean bweight as 3rd order polynomial of gestwks



```
> mp3 <- update( m, . ~ . - gestwks + poly(gestwks, 3) )
```

- ▶ The model is linear in parameters with 4 terms & 4 df.
- ▶ Otherwise good, but the tails do not behave well.

Penalized spline model with cross-validation



```
> library(mgcv)
> mpen <- gam( bweight ~ s(gestwks), data = births )
```

- ▶ Looks quite nice.
- ▶ Model degrees of freedom ≈ 4.2 ; almost 4, as in the 3rd degree polynomial model

What was covered

- ▶ A wide range of models from simple linear regression to splines.
- ▶ R functions fitting linear and generalized models: `lm()` and `glm()`.
- ▶ Parametrization of categorical explanatory factors; contrast matrices.
- ▶ Extracting results and predictions: `ci.lin()`, `fitted()`, `predict()`, ...
- ▶ Model diagnostics: `resid()`, `plot.lm()`, ...



Introduction to splines

Martyn Plummer

International Agency for Research on Cancer
Lyon, France

SPE 2017, Tartu

Overview

Join the dots

Brownian motion

Smoothing splines

Conclusions

Outline


Join the dots

Brownian motion

Smoothing splines

Conclusions

Join the dots



Join the dots
Brownian motion
Smoothing splines
Conclusions

Join the dots

International Agency for Research on Cancer
World Health Organization

Join the dots
Brownian motion
Smoothing splines
Conclusions

What does the penalty mean?

- The contribution to the penalty at each point depends on the steepness of the curve (represented by a colour gradient)
- Any deviation from a straight line between the two fixed points will incur a higher penalty overall.

International Agency for Research on Cancer
World Health Organization

Join the dots
Brownian motion
Smoothing splines
Conclusions

Linear interpolation

- Suppose a dose response curve is known exactly at certain points
- We can fill in the gaps (interpolate) by drawing a straight (linear) line between adjacent points

International Agency for Research on Cancer
World Health Organization

Join the dots
Brownian motion
Smoothing splines
Conclusions

Extrapolation

- Linear interpolation fits a linear dose-response curve exactly
- But it breaks down when we try to extrapolate

International Agency for Research on Cancer
World Health Organization

Join the dots
Brownian motion
Smoothing splines
Conclusions

Linear interpolation

- Suppose a dose response curve is known exactly at certain points
- We can fill in the gaps (interpolate) by drawing a straight (linear) line between adjacent points

International Agency for Research on Cancer
World Health Organization

Join the dots
Brownian motion
Smoothing splines
Conclusions

Extrapolation

Linear interpolation

- Linear interpolation fits a linear dose-response curve exactly
- But it breaks down when we try to extrapolate

International Agency for Research on Cancer
World Health Organization

Join the dots
Brownian motion
Smoothing splines
Conclusions

Why linear interpolation?

Out of all possible curves that go through the observed points, linear interpolation is the one that minimizes the penalty function

$$\int \left(\frac{\partial f}{\partial x} \right)^2 dx$$

International Agency for Research on Cancer
World Health Organization

Join the dots
Brownian motion
Smoothing splines
Conclusions

Extrapolation

Extrapolation - not what we want


- Linear interpolation fits a linear dose-response curve exactly
- But it breaks down when we try to extrapolate

International Agency for Research on Cancer
World Health Organization

Join the dots Brownian motion Smoothing splines Conclusions

Extrapolation

We want this




- Linear interpolation fits a linear dose-response curve exactly
- But it breaks down when we try to extrapolate

International Agency for Research on Cancer
World Health Organization

Join the dots Brownian motion Smoothing splines Conclusions

What does the roughness penalty mean?

Visualisation of the penalty function



- The contribution to the penalty at each point depends on the curvature (represented by a colour gradient)
- A straight line has no curvature, hence zero penalty.
- Sharp changes in the slope are heavily penalized.

International Agency for Research on Cancer
World Health Organization

Join the dots Brownian motion Smoothing splines Conclusions

Why does linear interpolation break down?

- The penalty function

$$\int \left(\frac{\partial f}{\partial x} \right)^2 dx$$


penalizes the steepness of the curve

- Minimizing the penalty function gives us the "flattest" curve that goes through the points.
 - In between two observations the flattest curve is a straight line.
 - Outside the range of the observations the flattest curve is completely flat.

International Agency for Research on Cancer
World Health Organization

Join the dots Brownian motion Smoothing splines Conclusions

An interpolating cubic spline



- The smoothest curve that goes through the observed points is a cubic spline.

International Agency for Research on Cancer
World Health Organization

Join the dots Brownian motion Smoothing splines Conclusions

A roughness penalty

- If we want a fitted curve that extrapolates a linear trend then we want to minimize the curvature.


$$\int \left(\frac{\partial^2 f}{\partial x^2} \right)^2 dx$$

- Like the first penalty function but uses the second derivative of f (i.e. the curvature).
- This is a roughness penalty.

International Agency for Research on Cancer
World Health Organization

Join the dots Brownian motion Smoothing splines Conclusions

An interpolating cubic spline



- The smoothest curve that goes through the observed points is a cubic spline.

International Agency for Research on Cancer
World Health Organization

Join the dots Brownian motion Smoothing splines Conclusions

A roughness penalty

- If we want a fitted curve that extrapolates a linear trend then we want to minimize the **curvature**.

$$\int \left(\frac{\partial^2 f}{\partial x^2} \right)^2 dx$$

- Like the first penalty function but uses the **second derivative** of f (i.e. the curvature).
- This is a roughness penalty.

International Agency for Research on Cancer
World Health Organization

Join the dots Brownian motion Smoothing splines Conclusions

Properties of cubic splines

- A cubic spline consists of a sequence of curves of the form

$$f(x) = a + bx + cx^2 + dx^3$$
 for some coefficients a, b, c, d , in between each observed point.
- The cubic curves are joined at the observed points (knots)
- The cubic curves match where they meet at the knots
 - Same value $f(x)$
 - Same slope $\partial f / \partial x$
 - Same curvature $\partial^2 f / \partial x^2$

International Agency for Research on Cancer
World Health Organization

Join the dots
Brownian motion
Smoothing splines
Conclusions


Outline

Join the dots
Brownian motion
Smoothing splines
Conclusions

International Agency for Research on Cancer
World Health Organization

Join the dots
Brownian motion
Smoothing splines
Conclusions

A partially observed Brownian motion



- Suppose we observe a Brownian motion at three points
- Grey lines show a sample of possible paths through the points
- The black line shows the average over all paths

International Agency for Research on Cancer
World Health Organization

Join the dots
Brownian motion
Smoothing splines
Conclusions


Brownian motion

- In 1827, botanist Robert Brown observed particles under the microscope moving randomly
- Theoretical explanation by Einstein (1905) in terms of water molecules
- Verified by Perrin (1908). Nobel prize in physics 1927.

International Agency for Research on Cancer
World Health Organization

Join the dots
Brownian motion
Smoothing splines
Conclusions

A partially observed Brownian motion




- Suppose we observe a Brownian motion at three points
- Grey lines show a sample of possible paths through the points
- The black line shows the average over all paths

International Agency for Research on Cancer
World Health Organization

Join the dots
Brownian motion
Smoothing splines
Conclusions

Evolution of 1-dimensional Brownian motion with time



- In mathematics a Brownian motion is a stochastic process that randomly goes up or down at any time point
- Also called a Wiener process after American mathematician Norbert Wiener.
- A Brownian motion is fractal – it looks the same if you zoom in and rescale

International Agency for Research on Cancer
World Health Organization

Join the dots
Brownian motion
Smoothing splines
Conclusions


Statistical model for linear interpolation

- Suppose the curve f is generated by the underlying model
$$f(x) = \alpha + \sigma W(x)$$
where W (for Wiener process) is a Brownian motion
- Then given points $(x_1, f(x_1)) \dots (x_n, f(x_n))$ the *expected value* of f is the curve we get from linear interpolation.

International Agency for Research on Cancer
World Health Organization

Join the dots
Brownian motion
Smoothing splines
Conclusions

A partially observed Brownian motion




- Suppose we observe a Brownian motion at three points
- Grey lines show a sample of possible paths through the points
- The black line shows the average over all paths

International Agency for Research on Cancer
World Health Organization

Join the dots
Brownian motion
Smoothing splines
Conclusions

Integrated Brownian motion



- The value of an integrated Brownian motion is the area under the curve (AUC) of a Brownian motion up to that point.
- AUC goes down when the Brownian motion takes a negative value.

International Agency for Research on Cancer
World Health Organization

Integrated Brownian motion with drift

Add a mean parameter and a linear trend (drift) to the integrated Brownian motion:


$$f(x) = \alpha + \beta x + \sigma \int_0^x W(z) dz$$

This more complex model is capable of modelling smooth curves.

The knot paradox

- There are no knots in the underlying model for a cubic natural spline.
- Knots are a result of the observation process.

A partially observed integrated Brownian motion with drift



- Grey lines show a sample of possible paths through the points
- The black line shows the average over all paths

Outline


Join the dots

Brownian motion

Smoothing splines


Conclusions

Zoom on the expected value



- The expected value is a cubic spline.
- Extrapolation beyond the boundary of the points is linear (natural spline).

Dose response with error




In practice we never know the dose response curve exactly at any point but always measure with error. A spline model is then a compromise between

- Model fit
- Smoothness of the spline

The smoothness paradox

- A cubic natural spline is the smoothest curve that goes through a set of points.
- But the underlying random process $f(x)$ is nowhere smooth.
- $f(x)$ is constantly changing its slope based on the value of the underlying Brownian motion.

Dose response with error



In practice we never know the dose response curve exactly at any point but always measure with error. A spline model is then a compromise between

- Model fit
- Smoothness of the spline

Fitting a smoothing spline

Minimize

$$\sum_i (y_i - f(x_i))^2 + \lambda \int \left(\frac{\partial^2 f}{\partial x^2} \right)^2 dx$$

Or, more generally

Deviance + λ * Roughness penalty

Size of tuning parameter λ determines compromise between model fit (small λ) and smoothness (large λ).

Spline models done well

- A knot for every observed value (remember: knots are a product of the observation process).
- Use penalization: find the right compromise between model fit and model complexity.
- In practice we can get a good approximation to this “ideal” model with fewer knots.
- This assumption should be tested

How to choose the tuning parameter λ

This is a statistical problem. There are various statistical approaches:

- Restricted maximum likelihood (REML)
- Cross-validation
- Bayesian approach (with prior on smoothness)

At least the first two should be available in most software.

Spline models in R

- Do not use the splines package.
- Use the `gam` function from the `mgcv` package to fit your spline models.
- The `gam` function chooses number and placement of knots for you and estimates the size of the tuning parameter λ automatically.
- You can use the `gam.check` function to see if you have enough knots. Also re-fit the model explicitly setting a larger number of knots (e.g. `double`) to see if the fit changes.

Outline


Join the dots

Brownian motion

Smoothing splines

Conclusions

Penalized spline




- A `gam` fit to some simulated data
- Model has 9 degrees of freedom
- Smoothing reduces this to 2.88 effective degrees of freedom

Spline models done badly

- Choose number and placement of knots
- Create a spline bases
- Use spline basis as the design matrix in a generalized linear model.
- Without penalization, model will underfit (too few knots) or overfit (too many knots)
- Placement of knots may create artefacts in the dose-response relationship

Penalized spline




- A `gam` fit to some simulated data
- Model has 9 degrees of freedom
- Smoothing reduces this to 2.88 effective degrees of freedom

Join the dots
Brownian motion
Smoothing splines
Conclusions

Unpenalized spline

Some simulated data



- An unpenalized spline using the same spline basis as the gam fit.
- Model has 9 degrees of freedom

International Agency for Research on Cancer
World Health Organization

Overview of graphics systems
Device handling
Base graphics
Lattice graphics
Grid graphics

Graphics Systems in R


R has several different graphics systems:

- ▶ Base graphics (the `graphics` package)
- ▶ Lattice graphics (the `lattice` package)
- ▶ Grid graphics (the `grid` package)
- ▶ Grammar of graphics (the `ggplot2` package)

Why so many? Which one to use?

Join the dots
Brownian motion
Smoothing splines
Conclusions

Unpenalized spline




- An unpenalized spline using the same spline basis as the gam fit.
- Model has 9 degrees of freedom

International Agency for Research on Cancer
World Health Organization

Overview of graphics systems
Device handling
Base graphics
Lattice graphics
Grid graphics

Base Graphics

- ▶ The oldest graphics system in R.
- ▶ Based on S graphics (Becker, Chambers and Wilks, *The New S Language*, 1988)
- ▶ Implemented in the base package `graphics`
 - ▶ Loaded automatically so always available
- ▶ Ink on paper model; once something is drawn “the ink is dry” and it cannot be erased or modified.



More Advanced Graphics in R

Martyn Plummer

International Agency for Research on Cancer
Lyon, France

SPE 2017, Tartu

International Agency for Research on Cancer
World Health Organization

Overview of graphics systems
Device handling
Base graphics
Lattice graphics
Grid graphics

Lattice Graphics

- ▶ A high-level data visualization system with an emphasis on multivariate data
- ▶ An implementation of Trellis graphics, first described by William Cleveland in the book *Visualizing Data*, 1993.
- ▶ Implemented in the base package `lattice`.
- ▶ More fully described by the `lattice` package author Deepayan Sarkar in the book *Lattice: Multivariate Data Visualization with R*, 2008.

Overview of graphics systems
Device handling
Base graphics
Lattice graphics
Grid graphics

Outline

- Overview of graphics systems
- Device handling
- Base graphics
- Lattice graphics
- Grid graphics

Overview of graphics systems
Device handling
Base graphics
Lattice graphics
Grid graphics

Grammar of Graphics

- ▶ Originally described by Leland Wilkinson in the book *The Grammar of Graphics*, 1999 and implemented in the statistical software nVizn (part of SPSS)
- ▶ Statistical graphics, like natural languages, can be broken down into components that must be combined according to certain rules.
- ▶ Provides a *pattern language* for graphics:
 - ▶ geometries, statistics, scales, coordinate systems, aesthetics, themes, ...
- ▶ Implemented in R in the CRAN package `ggplot2`
- ▶ Described more fully by the `ggplot2` package author Hadley Wickham in the book *ggplot2: Elegant Graphics for Data Analysis*, 2009.

Grid Graphics

- ▶ A complete rewrite of the graphics system of R, independent of base graphics.
- ▶ Programming with graphics:
 - ▶ Grid graphics commands create graphical objects (Grobs)
 - ▶ Printing a Grob displays it on a graphics device
 - ▶ Functions can act on grobs to modify or combine them
- ▶ Implemented in the base package `grid`, and extended by CRAN packages `gridExtra`, `gridDebug`, ...
- ▶ Described by the package author Paul Murrell in the book *R Graphics (2nd edition)*, 2011.

Writing Graphs to Files

There are also non-interactive graphics devices that write to a file instead of the screen.

`pdf` produces Portable Document Format files

`win.metafile` produces Windows metafiles that can be included in Microsoft Office documents (windows only)

`postscript` produces postscript files

`png`, `bmp`, `jpeg` all produce bitmap graphics files

- ▶ Turn off a graphics device with `dev.off()`. Particularly important for non-interactive devices.
- ▶ Plots may look different in different devices

Putting It All Together

- ▶ Base graphics are the default, and are used almost exclusively in this course
- ▶ `lattice` and `ggplot2` are alternate, high-level graphics packages
- ▶ `grid` provides alternate low-level graphics functions.
 - ▶ A *domain-specific language* for graphics within R
 - ▶ Underlies both `lattice` and `ggplot2`
 - ▶ Experts only
- ▶ All graphics packages take time to learn...

Types of Plotting Functions

- ▶ High level
 - ▶ Create a new page of plots with reasonable default appearance.
- ▶ Low level
 - ▶ Draw elements of a plot on an existing page:
 - ▶ Draw title, subtitle, axes, legend ...
 - ▶ Add points, lines, text, math expressions ...
- ▶ Interactive
 - ▶ Querying mouse position (`locator`), highlighting points (`identify`)

Graphics Devices

Graphics devices are used by all graphics systems (base, `lattice`, `ggplot2`, `grid`).

- ▶ Plotting commands will draw on the current *graphics device*
- ▶ This default graphics device is a window on your screen:
 - On Windows `windows()`
 - On Unix/Linux `x11()`
 - On Mac OS X `quartz()`
 It normally opens up automatically when you need it.
- ▶ You can have several graphics devices open at the same time (but only one is current)

Basic x-y Plots

- ▶ The `plot` function with one or two numeric arguments
- ▶ Scatterplot or line plot (or both) depending on `type` argument: "l" for lines, "p" for points (the default), "b" for both, plus quite a few more
- ▶ Also: formula interface, `plot(y~x)`, with arguments similar to the modeling functions like `lm`

Graphics Device in RStudio

RStudio has its own graphics device `RStudioGD` built into the graphical user interface

- ▶ You can see the contents in a temporary, larger window by clicking the zoom button.
- ▶ You can write the contents directly to a file with the export menu
- ▶ Sometimes small size of the `RStudioGD` causes problems. Open up a new device calling `RStudioGD()`. This will appear in its own window, free from the GUI.

Customizing Plots

- ▶ Most plotting functions take optional parameters to change the appearance of the plot
 - ▶ e.g., `xlab`, `ylab` to add informative axis labels
- ▶ Most of these parameters can be supplied to the `par()` function, which changes the default behaviour of subsequent plotting functions
- ▶ Look them up via `help(par)`! Here are some of the more commonly used:
 - ▶ Point and line characteristics: `pch`, `col`, `lty`, `lwd`
 - ▶ Multiframe layout: `mflow`, `mfc`
 - ▶ Axes: `xlim`, `ylim`, `xaxt`, `yaxt`, `log`

Adding to Plots


- ▶ `title()` add a title above the plot
- ▶ `points()`, `lines()` adds points and (poly-)lines
- ▶ `text()` text strings at given coordinates
- ▶ `abline()` line given by coefficients (*a* and *b*) or by fitted linear model
- ▶ `axis()` adds an axis to one edge of the plot region. Allows some options not otherwise available.

Demo 2

```
x <- runif(50,0,2)
y <- runif(50,0,2)
plot(x, y, main="Main title", sub="subtitle",
      xlab="x-label", ylab="y-label")
text(0.6,0.6,"text at (0.6,0.6)")
abline(h=.6,v=.6)
for (side in 1:4)
  mtext(-1:4,side=side,at=.7,line=-1:4)
mtext(paste("side",1:4), side=1:4, line=-1,font=2)
```

Approach to Customization

- ▶ Start with default plots
- ▶ Modify parameters (using `par()` settings or plotting arguments)
- ▶ Add more graphics elements. Notice that there are graphics parameters that turn things *off*, e.g. `plot(x, y, xaxt="n")` so that you can add completely customized axes with the `axis` function.
- ▶ Put all your plotting commands in a script or inside a function so you can start again



Demo 1

```
library(ISwR)
par(mfrow=c(2,2))
matplot(intake)
matplot(t(intake))
matplot(t(intake),type="b")
matplot(t(intake),type="b",pch=1:11,col="black",
        lty="solid", xaxt="n")
axis(1,at=1:2,labels=names(intake))
```

The `lattice` package provides functions that produce similar plots to base graphics (with a different “look and feel”)

base	lattice
<code>plot</code>	<code>xyplot</code>
<code>hist</code>	<code>histogram</code>
<code>boxplot</code>	<code>bwplot</code>
<code>barplot</code>	<code>barchart</code>
<code>heatmap</code> , <code>contour</code>	<code>levelplot</code>
<code>dotchart</code>	<code>dotplot</code>

Lattice graphics can also be used to explore *multi-dimensional data*

Margins


- ▶ R sometimes seems to leave too much empty space around plots (especially in multi-frame layouts).
- ▶ There is a good reason for it: You might want to put something there (titles, axes).
- ▶ This is controlled by the `mar` parameter. By default, it is `c(5,4,4,2)+0.1`
 - ▶ The units are *lines of text*, so depend on the setting of `pointsize` and `cex`
 - ▶ The sides are indexed in clockwise order, starting at the bottom (1=bottom, 2=left, 3=top, 4=right)
- ▶ The `mtext` function is designed to write in the margins of the plot
- ▶ There is also an *outer margin* settable via the `oma` parameter. Useful for adding overall titles etc. to `multiframe` plots

Panels

- ▶ Plotting functions in `lattice` consistently use a formula interface, e.g. `y~x` to plot *y* against *x*
- ▶ The formula allows conditioning variables, e.g. `y~x|g1*g2*...`
- ▶ Conditioning variables create an array of *panels*,
 - ▶ One panel for each value of the conditioning variables
 - ▶ Continuous conditioning variables are divided into *shingles* (slightly overlapping ranges, named after the roof covering)
 - ▶ All panels have the same scales on the *x* and *y* axes.


Ozone Concentration by Solar Radiation

```
xyplot(log(Ozone)~Solar.R, data=airquality)
```



With Custom Panel


```
xyplot(log(Ozone)~Solar.R | equal.count(Temp),
panel=mypanel, data=airquality)
```



Each panel shows a scatter plot (`panel.xyplot`) and a regression line (`panel.lmline`)

Conditioned on Temperature

```
xyplot(log(Ozone)~Solar.R | equal.count(Temp),
data=airquality)
```




A Few Words on Grid Graphics

- ▶ Experts only, but ...
- ▶ Recall that `lattice` and `ggplot2` both use `grid`
- ▶ The key concepts you need are *grobs* and *viewports*

Coloured by Month

```
xyplot(log(Ozone)~Solar.R | equal.count(Temp),
group=Month, data=airquality)
```



Grobs: Graphical Objects

- ▶ Grobs are created by plotting functions in `grid`, `lattice`, `ggplot2`
- ▶ Grobs are only displayed when they are printed
- ▶ Grobs can be modified or combined before being displayed
- ▶ The `ggplot2` package uses the `+` operator to combine grobs representing different elements of the plot

Customizing Panels

- ▶ What goes inside each panel of a Lattice plot is controlled by a *panel function*
- ▶ There are many standard functions: `panel.xyplot`, `panel.lmline`, etc.
- ▶ You can write your own panel functions, most often by combining standard ones

```
mypanel <- function(x,y,...){
  panel.xyplot(x,y,...) #Scatter plot
  panel.lmline(x,y,type="l") #Regression line
}
```

Viewports

- ▶ The plotting region is divided into viewports
- ▶ Grobs are displayed inside a viewport
- ▶ The panels in lattice graphics are examples of viewports, but in general
 - ▶ Viewports can be different sizes (inches, centimetres, lines of text, or relative units)
 - ▶ Each viewport may have its own coordinate systems

Statistical Practice in Epidemiology 2017


Survival analysis with competing risks

Janne Pitkaniemi
(EL)

1/ 55

Set-up of classical survival analysis

- ▶ **Two-state model:** only one type of event changes the initial state.
- ▶ Major applications: analysis of lifetimes since birth and of survival times since diagnosis of a disease until death from any cause.



- ▶ **Censoring:** Death and final lifetime not observed for some subjects due to emigration or closing the follow-up while they are still alive

5/ 55

Points to be covered

1. Survival or time to event data & censoring.
2. Distribution concepts for times to event: survival, hazard and cumulative hazard,
3. Competing risks: event-specific cumulative incidences & hazards.
4. Kaplan–Meier and Aalen–Johansen estimators.
5. Regression modelling of hazards: Cox model.
6. Packages `survival`, `mstate`, `cmprisk`.
7. Functions `Surv()`, `survfit()`, `plot.survfit()`, `coxph()`, `Cuminc()`.

Points not to be covered – many!

2/ 55

Distribution concepts: survival function

Cumulative distribution function (CDF) $F(t)$ and density function $f(t) = F'(t)$ of survival time T :

$$F(t) = P(T \leq t) = \int_0^t f(u) du$$

= **risk** or probability that the event occurs by t .

Survival function

$$S(t) = 1 - F(t) = P(T > t) = \int_t^\infty f(u) du,$$

= probability of avoiding the event at least up to t (the event occurs only after t).

6/ 55

Survival time – time to event

Let T be the **time** spent in a given **state** from its beginning till a certain **endpoint** or **outcome event** or **transition** occurs, changing the state to another.

(`lex.Cst` – `lex.dur` – `lex.Xst`)

Examples of such times and outcome events:

- ▶ lifetime: birth → death,
- ▶ duration of marriage: wedding → divorce,
- ▶ healthy exposure time: start of exposure → onset of disease,
- ▶ clinical survival time: diagnosis of a disease → death.

3/ 55

Distribution concepts: hazard function

The **hazard rate** or **intensity** function $h(t)$

$$\begin{aligned} \lambda(t) &= \lim_{\Delta \rightarrow 0} P(t < T \leq t + \Delta | T > t) / \Delta \\ &= \lim_{\Delta \rightarrow 0} \frac{P(t < T \leq t + \Delta)}{P(T > t)} \frac{1}{\Delta} = \frac{f(t)}{S(t)} \end{aligned}$$

≈ the conditional probability that the event occurs in a short interval $(t, t + \Delta]$, given that it does not occur before t , divided by interval length.

In other words, during a short interval

risk of event ≈ hazard × interval length

7/ 55

Ex. Survival of 338 oral cancer patients

Important variables:

- ▶ **time** = duration of patientship from diagnosis (**entry**) till death or censoring,
- ▶ **event** = indicator for the outcome and its observation at the end of follow-up (**exit**):
0 = censoring,
1 = death from oral cancer,
2 = death from some other cause.

Special features:

- ▶ Several possible endpoints, *i.e.* alternative causes of death, of which only one is realized.
- ▶ Censoring – incomplete observation of the survival time.

4/ 55

Distribution: cumulative hazard etc.

The **cumulative hazard** (or integrated intensity):

$$\Lambda(t) = \int_0^t \lambda(v) dv$$

Connections between the functions:

$$\begin{aligned} \lambda(t) &= \frac{f(t)}{1 - F(t)} = -\frac{S'(t)}{S(t)} = -\frac{d \log[S(t)]}{dt}, \\ \Lambda(t) &= -\log[S(t)], \\ S(t) &= \exp\{-\Lambda(t)\} = \exp\left\{-\int_0^t \lambda(v) dv\right\}, \\ f(t) &= \lambda(t)S(t) \\ F(t) &= 1 - \exp\{-\Lambda(t)\} \\ &= \int_0^t \lambda(v)S(v) dv \end{aligned}$$

8/ 55

Observed data on survival times

For individuals $i = 1, \dots, n$ let

T_i = true time to outcome event,

U_i = true time to censoring.

Censoring is assumed **noninformative**, i.e. independent from occurrence of events.

We observe


$y_i = \min\{T_i, U_i\}$, i.e. the exit time, and

$\delta_i = 1_{\{T_i < U_i\}}$, indicator (1/0) for the outcome event occurring first, before censoring.

Censoring must properly be taken into account in the statistical analysis.

9/ 55

Oral cancer: Kaplan-Meier estimates



13/ 55

Approaches for analysing survival time

- **Parametric model** (like Weibull, gamma, etc.) on hazard rate $\lambda(t) \rightarrow$ Likelihood:

$$L = \prod_{i=1}^n \lambda(y_i)^{\delta_i} S(y_i) = \prod_{i=1}^n \lambda(y_i)^{\delta_i} \exp\{-\Lambda(y_i)\}$$


$$= \exp\left\{\sum_{i=1}^n [\delta_i \log \lambda(y_i) - \Lambda(y_i)]\right\}$$

- **Piecewise constant rate model** on $\lambda(t)$
– see Bendix's lecture on time-splitting.
- **Non-parametric methods**, like Kaplan-Meier (KM) estimator of survival curve $S(t)$ and Cox proportional hazards model on $\lambda(t)$.

10/ 55

Estimated $F(t) = 1 - S(t)$ on variable scales

- KM curve of survival $S(t)$ is the most popular.
- Informative are also graphs for estimates of $F(t) = 1 - S(t)$, i.e. CDF
 $\Lambda(t) = -\log[1 - F(t)]$, cumulative hazard,
 $\log[\Lambda(t)]$, cloglog transform of CDF.



14/ 55

R package survival


Tools for analysis with one outcome event.

- `Surv(time, event) -> subj`
creates a **survival object** subj, containing pairs (y_i, δ_i) ,
- `Surv(entry, exit, event) -> subj2`
creates a survival object from entry and exit times,
- `survfit(subj ~ x) -> sfo`
creates a **survfit** object sfo containing KM or other non-parametric estimates (also from a fitted Cox model),
- `plot(sfo)`
plot method for survival curves and related graphs,
- `coxph(subj ~ x1 + x2)`
fits a Cox model with covariates x1 and x2.
- `survreg()` – parametric survival models.

11/ 55

Competing risks model: causes of death

- Often the interest is focused on the risk or hazard of dying from one specific cause.
- That cause may eventually not be realized, because a **competing cause** of death hits first.



- Generalizes to several competing causes.

15/ 55

Ex. Oral cancer data (cont'd)

```
> orca$suob <- Surv(orca$time, 1*(orca$event > 0) )
> orca$suob[1:7] # + indicates censored observation
[1] 5.081+ 0.419 7.915 2.480 2.500 0.167 5.925+

> km1 <- survfit( suob ~ 1, data = orca)
> km1 # brief summary
records n.max n.start events median 0.95LCL 0.95UCL
338.00 338.00 338.00 229.00 5.42 4.33 6.92

> summary(km1) # detailed KM-estimate

time n.risk n.event survival std.err lower 95% CI upper 95% CI
0.085 338 2 0.9941 0.00417 0.9859 1.000
0.162 336 2 0.9882 0.00588 0.9767 1.000
0.167 334 4 0.9763 0.00827 0.9603 0.993
0.170 330 2 0.9704 0.00922 0.9525 0.989
0.246 328 1 0.9675 0.00965 0.9487 0.987
...
```

12/ 55

Competing events & competing risks

In many epidemiological and clinical contexts there are competing events that may occur before the target event and remove the person from the population at risk for the event, e.g.

- **target event**: occurrence of endometrial cancer,
competing events: hysterectomy or death.
- **target event**: relapse of a disease (ending the state of remission),
competing event: death while still in remission.
- **target event**: divorce,
competing event: death of either spouse.

16/ 55

Event-specific quantities

Cumulative incidence function (CIF) or **subdistribution function** for event c :

$$F_c(t) = P(T \leq t \text{ and } C = c), \quad c = 1, 2,$$

subdensity function $f_c(t) = dF_c(t)/dt$

From these one can recover

- ▶ $F(t) = \sum_c F_c(t)$, CDF of event-free survival time T , i.e. cumulative risk of any event by t .
- ▶ $S(t) = 1 - F(t)$, **event-free survival function**, i.e. probability of avoiding all events by t

17/ 55

Example: Risk of lung cancer by age a ?

- ▶ Empirical **cumulative rate** $CR(a) = \sum_{k < a} I_k \Delta_k$, i.e. ageband-width (Δ_k) weighted sum of empirical age-specific incidence rates I_k up to a given age a = estimate of cumulative hazard $\Lambda_c(a)$.
- ▶ Nordcan & Globocan give “**cumulative risk**” by 75 y of age, computed from $1 - \exp\{-CR(75)\}$, as an estimate of the probability of getting cancer before age 75 y, assuming that death were avoided by that age. This is based on deriving “net risk” from cumulative hazard: $F_c^*(a) = 1 - \exp\{-\Lambda_c(a)\}$.
- ▶ Yet, cancer occurs in a mortal population.
- ▶ As such $CR(75)$ is a sound age-standardized summary measure for comparing cancer incidence across populations based on a neutral standard population.

21/ 55

Event-specific quantities (cont'd)

Event- or cause-specific hazard function

$$\lambda_c(t) = \lim_{\Delta \rightarrow 0} \frac{P(t < T \leq t + \Delta \text{ and } C = c \mid T > t)}{\Delta} = \frac{f_c(t)}{1 - F(t)}$$

≈ Risk of event c in a short interval $(t, t + \Delta]$, given avoidance of all events up to t , per interval length.


Event- or cause-specific cumulative hazard

$$\Lambda_c(t) = \int_0^t \lambda_c(v) dv$$

18/ 55

Example. Male lung cancer in Denmark

Event-specific hazards $\lambda_c(a)$ by age estimated by age-spec. rates of death and lung ca., resp.



22/ 55

Event-specific quantities (cont'd)

- ▶ CIF = risk of event c over risk period $[0, t]$ in the presence of competing risks, also obtained

$$F_c(t) = \int_0^t \lambda_c(v) S(v) dv, \quad c = 1, 2,$$

- ▶ Depends on the hazard of the competing event, too, via

$$S(t) = \exp \left\{ - \int_0^t [\lambda_1(v) + \lambda_2(v)] dv \right\} = \exp \{ -\Lambda_1(t) \} \times \exp \{ -\Lambda_2(t) \}.$$


Hazard of the subdistribution

$$\gamma_c(t) = f_c(t) / [1 - F_c(t)]$$

- ▶ Is not the same as $\lambda_c(t) = f_c(t) / [1 - F(t)]$,
- ▶ Interpretation tricky!

19/ 55

Cumulative incidence of lung cancer by age



Both CR and $1 - \exp(-CR)$ tend to overestimate the real cumulative incidence CI after 60 y.

23/ 55

Warning of “net risk” and “cause-specific survival”

- ▶ The “**net risk**” of outcome c by time t , assuming hypothetical elimination of competing risks, is often defined as

$$F_c^*(t) = 1 - S_c^*(t) = 1 - \exp\{-\Lambda_c(t)\}$$

- ▶ In clinical survival studies, function $S_c^*(t)$ is often called “**cause-specific survival**”, and estimated by KM, but treating competing deaths as censorings.
- ▶ Yet, these *-functions, $F_c^*(t)$ and $S_c^*(t)$, lack proper probability interpretation when competing risks exist.
- ▶ Hence, their use and naive KM estimation should be viewed critically (Andersen & Keiding, *Stat Med*, 2012)

20/ 55

Analysis with competing events

Let U_i = censoring time, T_i = time to first event, and C_i = variable for event 1 or 2. We observe

- ▶ $y_i = \min\{T_i, U_i\}$, i.e. the exit time, and
- ▶ $\delta_{ic} = 1_{\{T_i < U_i \text{ \& } C_i = c\}}$, indicator (1/0) for event c being first observed, $c = 1, 2$.

Likelihood factorizes into event-specific parts:

$$L = \prod_{i=1}^n \lambda_1(y_i)^{\delta_{i1}} \lambda_2(y_i)^{\delta_{i2}} S(y_i) = L_1 L_2 = \prod_{i=1}^n \lambda_1(y_i)^{\delta_{i1}} \exp\{-\Lambda_1(y_i)\} \times \prod_{i=1}^n \lambda_2(y_i)^{\delta_{i2}} \exp\{-\Lambda_2(y_i)\}$$

⇒ If $\lambda_1(y_i)$ and $\lambda_2(y_i)$ have no common parameters, they may be fitted separately treating competing events as censorings.
– Still, avoid estimating “net risks” from $F_c^* = 1 - \exp(-\Lambda_c)$!

24/ 55

Non-parametric estimation of CIF

- ▶ Let $t_1 < t_2 < \dots < t_K$ be the K distinct time points at which any outcome event was observed, Let also $\tilde{S}(t)$ be KM estimator for overall $S(t)$.
- ▶ **Aalen-Johansen estimator (AJ)** for the cumulative incidence function $F(t)$ is obtained as

$$\tilde{F}_c(t) = \sum_{t_k \leq t} \frac{D_{kc}}{n_k} \times \tilde{S}(t_{k-1}), \quad \text{where}$$

n_k = size of the risk set at t_k ($k = 1, \dots, K$),
 D_{kc} = no. of cases of event c observed at t_k .


- ▶ Naive KM estimator $\tilde{F}_c^*(t)$ of "net survival" treats competing events occurring first as censorings:

$$\tilde{F}_c^*(t) = 1 - \tilde{S}_c^*(t) = 1 - \prod_{t_k \leq t} \frac{n_k - D_{kc}}{n_k}$$

25/ 55

Ex. Survival from oral cancer

- ▶ AJ-estimates of CIFs (solid) for both causes.
- ▶ Naive KM-estimates of CIF (dashed) > AJ-estimates
- ▶ CIF curves may also be stacked (right).



NB. The sum of the naive KM-estimates of CIF exceeds 100% at 13 years!

29/ 55

R tools for competing risks analysis

Package `mstate`

- ▶ `Cuminc(time, status, ...)`:
AJ-estimates (and SEs) for each event type (status, value 0 indicating censoring)

Package `cmprsk`


- ▶ `cuminc(ftime, fstatus, ...)` computes CIF-estimates, `plot.cuminc()` plots them.
- ▶ `crr()` fits Fine-Gray models for the hazard $\gamma_c(t)$ of the subdistribution

Package `Epi` – Lexis tools for multistate analyses

- ▶ will be advertised by Bendix!

26/ 55

Ex. CIFs by cause in men and women



CIF for cancer higher in women (chance?) but for other causes higher in men (no surprise).

30/ 55

Ex. Survival from oral cancer

- ▶ Creating a Lexis object with two outcome events and obtaining a summary of transitions

```
> orca.lex <- Lexis(exit = list(stime = time),
  exit.status = factor(event,
    labels = c("Alive", "Oral ca. death", "Other death") ),
  data = orca)
```

```
> summary(orca.lex)
```

Transitions:

To

From	Alive	Oral ca.	Other	Records:	Events:	Risk time:
Alive	109	122	107	338	229	1913.67

27/ 55

Regression models for time-to-event data

Consider only one outcome & no competing events

- ▶ Subject i ($i = 1, \dots, n$) has an own vector x_i that contains values (x_{i1}, \dots, x_{ip}) of a set of p continuous and/or binary covariate terms.
- ▶ In the spirit of generalized linear models we let $\beta = (\beta_1, \dots, \beta_p)$ be regression coefficients and build a **linear predictor**

$$\eta_i = x_i^T \beta = \beta_1 x_{i1} + \dots + \beta_p x_{ip}$$


- ▶ Specification of outcome variable?
Distribution (family)? Expectation? Link?

31/ 55

Box diagram for transitions

Interactive use of function `boxes()`.

```
> boxes(orca.lex)
```



28/ 55

Regression models (cont'd)

Survival regression models can be defined e.g. for

- (a) survival times directly

$$\log(T_i) = \eta_i + \epsilon_i, \quad \text{s.t. } \epsilon_i \sim F_0(t; \alpha)$$

where $F_0(t; \alpha)$ is some baseline model,

- (b) hazards, multiplicatively:

$$\lambda_i(t) = \lambda_0(t; \alpha) r(\eta_i), \quad \text{where}$$

$\lambda_0(t; \alpha)$ = baseline hazard and
 $r(\eta_i)$ = relative rate function, typically $\exp(\eta_i)$

- (c) hazards, additively:

$$\lambda_i(t) = \lambda_0(t; \alpha) + \eta_i.$$

32/ 55

Relative hazards model or Cox model

In model (b), the baseline hazard $\lambda_0(t, \alpha)$ may be given a parametric form (e.g. Weibull) or a piecewise constant rate (exponential) structure.

Often a parameter-free form $\lambda_0(t)$ is assumed. Then

$$\lambda_i(t) = \lambda_0(t) \exp(\eta_i),$$

specifies the **Cox model** or the **semiparametric proportional hazards model**.

$\eta_i = \beta_1 x_{i1} + \dots + \beta_p x_{ip}$ not depending on time.

Generalizations: **time-dependent** covariates $x_{ij}(t)$, and/or effects $\beta_j(t)$.

33 / 55

Predictions from the Cox model

- Individual survival *times* cannot be predicted but ind'l survival *curves* can. PH model implies:

$$S_i(t) = [S_0(t)]^{\exp(\beta_1 x_{i1} + \dots + \beta_p x_{ip})}$$

- Having estimated β by partial likelihood, the baseline $S_0(t)$ is estimated by Breslow method
- From these, a survival curve for an individual with given covariate values is predicted.
- In R: `pred <- survfit(mod, newdata=...)` and `plot(pred)`, where `mod` is the fitted coxph object, and `newdata` specifies the covariate values.

37 / 55

PH model: interpretation of parameters

Present the model explicitly in terms of x 's and β 's.

$$\lambda_i(t) = \lambda_0(t) \exp(\beta_1 x_{i1} + \dots + \beta_p x_{ip})$$

Consider two individuals, i and i' , having the same values of all other covariates except the j^{th} one.

The ratio of hazards is constant:

$$\frac{\lambda_i(t)}{\lambda_{i'}(t)} = \frac{\exp(\eta_i)}{\exp(\eta_{i'})} = \exp\{\beta_j(x_{ij} - x_{i'j})\}.$$

Thus $e^{\beta_j} = \text{HR}_j = \text{hazard ratio}$ or relative rate associated with a unit change in covariate X_j .

34 / 55

Proportionality of hazards?

- Consider two groups g and h defined by one categorical covariate, and let $\rho > 0$.

If $\lambda_g(t) = \rho \lambda_h(t)$ then $\Lambda_g(t) = \rho \Lambda_h(t)$ and

$$\log \Lambda_g(t) = \log(\rho) + \log \Lambda_h(t),$$

thus log-cumulative hazards should be parallel!

⇒ Plot the estimated log-cumulative hazards and see whether they are sufficiently parallel.

- `plot(coxobj, ..., fun = 'cloglog')`
- Testing the proportionality assumptions: `cox.zph(coxobj)`.

38 / 55

Fitting the Cox PH model

Solution 1: Cox's **partial likelihood** $L^P = \prod_k L_k^P$, ignores $\lambda_0(t_k)$ when estimating β , using only the ordering of the observed event times t_k :

$$L_k^P = P(\text{the event occurs for } i_k \mid \text{an event at } t_k) \\ = \exp(\eta_{i_k}) / \sum_{i \in R(t_k)} \exp(\eta_i), \quad \text{where}$$

i_k = the subject encountering the event at t_k ,
 $R(t_k)$ = **risk set** = subjects at risk at t_k .


Solution 2: Piecewise constant rate model with dense division of the time axis, and fitting by Poisson regression using `glm()` (profile likelihood!).

35 / 55

Ex. Mortality of oral cancer patients

Complementary log-log plots of total mortality by

- age: 15-54 y (dash), 55-74 y (solid), 75+ y (longdash),
- sex: females (solid) and males (longdash).



39 / 55

Ex. Total mortality of oral ca. patients

Fitting Cox models with sex and sex + age.

```
> cm0 <- coxph( suob ~ sex, data = orca)
> summary(cm0)
      coef exp(coef) se(coef)      z Pr(>|z|)
sexMale  0.126    1.134   0.134  0.94   0.35
      exp(coef) exp(-coef) lower .95 upper .95
sexMale      1.13      0.882   0.872   1.47

> cm1 <- coxph( suob ~ sex + age, data = orca)
> summary(cm1)
      coef exp(coef) exp(-coef) lower .95 upper .95
sexMale  1.49      0.669      1.14   1.96
age      1.04      0.960      1.03   1.05
```

The M/F contrast visible only after age-adjustment.

36 / 55

Non-proportionality w.r.t. one covariate?

If the covariate is not an exposure of interest, but needs to be adjusted for → fit a **stratified** model.

Allows different baseline hazards, but same relative effects of other covariates in each strata.

```
> cm2 <- coxph( suob ~ sex + strata(age3), data = orca)
> summary(cm2)
```

```
      exp(coef) exp(-coef) lower .95 upper .95
sexMale      1.35      0.74      1.03   1.77
```

If the covariate *is* a factor of interest, one may consider transformations of it – or a completely different model: a *non-proportional* one!

40 / 55

Modelling with competing risks

Main options, providing answers to different questions.

- (a) Cox model for event-specific hazards
 $\lambda_c(t) = f_c(t)/[1 - F(t)]$, when e.g. the interest is in the biological effect of the prognostic factors on the fatality of the very disease that often leads to the relevant outcome.
- (b) **Fine-Gray model** for the hazard of the subdistribution
 $\gamma_c(t) = f_c(t)/[1 - F_c(t)]$ when we want to assess the impact of the factors on the overall cumulative incidence of event c .
 - Function `crr()` in package `cmprsk`.

41/ 55

Estimation of Relative Survival

Four different approaches has been developed. They differ in weighting aspects of cohort and period information to utilize available data.

1. **Complete approach** - patients diagnosed in a given period with prespecified potential follow-up (more historical, miss recent changes in survival)
2. **Cohort approach** - some follow-up times missed (censoring) in cohort approach, changing cohort miss rapidly changing outcomes.
3. **Period approach** - based on the most recent years, not considering follow-up outside given calendar time period
4. **Hybrid approach** - combining all methods, recent changes in late after diagnosis outcomes missed

45/ 55

Relative Survival - Motivation

- ▶ Survival is the primary outcome for **all cancer patients** in a population
 - trials are restricted by age and inclusion criteria
 - hospital patients represent only those entered
- ▶ A measure of **population level progress** in cancer control
 - + monitoring, success of childhood cancers
 - + inequalities, defined by sex, social class etc.
- ▶ Survival and duration of life after diagnosis one of the most important **measures of success in the management** (not only clinical treatment) of cancer patients

42/ 55

Estimation of Relative Survival

Estimation of relative survival requires two data sources:

1. **(Cancer) registry data** of patients with date of diagnosis (and other covariates) and follow-up information on deaths (date)
2. **Demographic information** - population mortality tables transformed to survival

Statistical packages that can be used to estimate relative survival are

- ▶ STATA (`strel`, `stmp2`, `strs`, `stns`)
- ▶ R-package **popEpi** written in Finnish Cancer registry by Joonas Miettinen, Karri Seppä, Matti Rantanen and Janne Pitkaniemi. Available on CRAN and github.

46/ 55

Relative Survival - Practical Motivation

- ▶ Estimate of mortality associated with a diagnosis of a particular cancer **without the need for cause of death** information.
- ▶ If we had perfect cause-of-death information then treat those that die from another cause as censored at their time of death.
- ▶ The **quality of cause-of-death information varies** over time, between types of cancer and between regions/countries.
- ▶ Many cancer registries **do not record cause of death**.
- ▶ Cause of death is rarely a simple dichotomy.

43/ 55

Estimation of Relative Survival

Reference population mortality (tables) by sex, year and age group given by official statistics converted to survival

```
data(popmort)
pm <- data.frame(popmort)
names(pm) <- c("sex", "CAL", "AGE", "haz")
head(pm)
```

```
> head(popmort)
  sex year agegroup      haz
1:  0 1951         0 0.036363176
2:  0 1951         1 0.003616547
3:  0 1951         2 0.002172384
4:  0 1951         3 0.001581249
5:  0 1951         4 0.001180690
6:  0 1951         5 0.001070595
...
```

47/ 55

Relative Survival (RS) function

Rather than estimating cumulative distribution function $F(t) = P(T < t)$ we are more interested in survival function $S(t) = 1 - F(t)$

When the cause of death is not known an interesting quantity is

$$r(t) = \frac{S_O(t)}{S_P(t)},$$

here $S_O(t)$ is the observed survival from the cohort of interest and $S_P(t)$ is the expected (population) estimated from the population life tables

44/ 55

RS example

A cancer patient cohort *sire* with a twist pertaining female Finnish rectal cancer patients diagnosed between 1993-2012. *sire* is a `data.table` object in *popEpi*-package

sex	gender of the patient (1 = female)
bi.date	date of birth
dg.date	date of cancer diagnosis
ex.date	date of exit from follow-up (death or censoring)
status	status of the person at exit;
	0 alive;
	1 dead due to pertinent cancer;
	2 dead due to other causes
dg.age	age at diagnosis expressed as fractional years

The closing date for the pertinent data was 2012-12-31, meaning status information was available only up to that point - hence the maximum possible `ex.date` is 2012-12-31.

48/ 55

RS example

The six first observations from the sire data

```
> head(sire)
  sex  bi_date  dg_date  ex_date status  dg_age
1:   1 1952-05-27 1994-02-03 2012-12-31    0 41.68877
2:   1 1959-04-04 1996-09-20 2012-12-31    0 37.46378
3:   1 1958-06-15 1994-05-30 2012-12-31    0 35.95616
4:   1 1957-05-10 1997-09-04 2012-12-31    0 40.32055
5:   1 1957-01-20 1996-09-24 2012-12-31    0 39.67745
6:   1 1962-05-25 1997-05-17 2012-12-31    0 34.97808
```

49/ 55

RS example

Relative survival

person-time: 23993 --- events: 3636

Stratified by: 'sex'

	sex	Tstop	r.e2.lo	r.e2	r.e2.hi	SE.r.e2
1:	0	2.5	0.7046	0.7224	0.7393	0.008848
2:	0	5.0	0.6487	0.6706	0.6914	0.010890
3:	1	2.5	0.6756	0.6924	0.7085	0.008397
4:	1	5.0	0.5891	0.6087	0.6277	0.009853

```
>
```

53/ 55

RS example

Estimated survival (surv.obs) and 95% confidence interval (surv.obs.lo,surv.obs.hi) from the rectal cancer in females in Finland 2008-2012


```
library(PopEpi)
library(Epi)
library(survival)
par(mfcol=c(1,2))

data(sire)
x <- Lexis(entry = list(FUT = 0,
  AGE = dg_age,
  CAL = get.yrs(dg_date)),
  exit = list(CAL = get.yrs(ex_date)),
  data = sire[sire$dg_date < sire$ex_date, ],
  exit.status = factor(status, levels = 0:2,
    labels = c("alive", "canD", "othD")),
  merge = TRUE)
```

50/ 55

RS example

Observed and relative (net) survival curves



54/ 55

RS example (continue)

```
## observed survival
st <- survtab(Surv
  (time = FUT, event = lex.Xst) ~ sex,
  data = x,
  surv.type = "surv.obs",
  breaks = list(FUT = seq(0, 5, 1/12)))
st

st.e2 <- survtab.lex(
  Surv(time = FUT, event = lex.Xst) ~ sex,
  data = x,
  surv.type = "surv.rel",
  relsurv.method = "e2",
  breaks = list(FUT = seq(0, 5, 1/12)),
  pophaz = pm)
st.e2
```

51/ 55

Some references

- ▶ Collett. D. (2003). *Modelling Survival Data in Medical Research, 2nd Edition*. C&H/CRC.
- ▶ Bull, K., Spiegelhalter, D. (1997). Tutorial in biostatistics: Survival analysis in observational studies. *Statistics in Medicine* **16**: 1041-1074. (ignore the SPSS-appendix!)
- ▶ Andersen, P.K., et al. (2002). Competing risks as a multi-state model. *Statistical Methods in Medical Research*. **11**: 203-215.
- ▶ Putter, H., Fiocco, M., Geskus, R. (2007). Tutorial in biostatistics: Competing risks and multi-state models. *Statistics in Medicine* **26**: 2389-2430.
- ▶ Seppä K., Dyba T., Hakulinen T. (2015). *Cancer Survival Reference Module in Biomedical Sciences; Elsevier*
doi: 10.1016/B978-0-12-801238-3.02745-8

55/ 55

RS example

Estimated observed and relative survival (Ederer II,surv.obs) and 95% confidence interval (r.e2.lo, r.e2.hi)from the rectal cancer in females in Finland 2008-2012

Observed survival

```
> st
Totals:
person-time: 23993 --- events: 3636

Stratified by: 'sex'
  sex Tstop surv.obs.lo surv.obs surv.obs.hi SE.surv.obs
1:   0   2.5    0.6174  0.6328    0.6478    0.007751
2:   0   5.0    0.4962  0.5126    0.5288    0.008321
3:   1   2.5    0.6235  0.6389    0.6539    0.007748
4:   1   5.0    0.5006  0.5171    0.5334    0.008370
```

52/ 55

Representation of follow-up

Bendix Carstensen Steno Diabetes Center
Gentofte, Denmark
<http://BendixCarstensen.com>

University of Tartu,

June 2017

<http://BendixCarstensen.com/SPE>

1/ 40

Representation of follow-up


Bendix Carstensen

Representation of follow-up

University of Tartu,

June 2017

<http://BendixCarstensen.com/SPE>



Probability

$$P(d \text{ at } t_x | \text{entry } t_0)$$

$$\begin{aligned} &= P(\text{surv } t_0 \rightarrow t_1 | \text{entry } t_0) \\ &\times P(\text{surv } t_1 \rightarrow t_2 | \text{entry } t_1) \\ &\times P(d \text{ at } t_x | \text{entry } t_2) \end{aligned}$$

log-Likelihood

$$d \log(\lambda) - \lambda y$$

$$\begin{aligned} &= 0 \log(\lambda) - \lambda y_1 \\ &+ 0 \log(\lambda) - \lambda y_2 \\ &+ d \log(\lambda) - \lambda y_3 \end{aligned}$$

Representation of follow-up (time-split)


5 / 40

Follow-up and rates

- ▶ In follow-up studies we estimate rates from:
 - ▶ D — events, deaths
 - ▶ Y — person-years
 - ▶ $\lambda = D/Y$ rates
 - ▶ ... empirical counterpart of intensity — **estimate**
- ▶ Rates differ between persons.
- ▶ Rates differ **within** persons:
 - ▶ By age
 - ▶ By calendar time
 - ▶ By disease duration
 - ▶ ...
- ▶ Multiple timescales.
- ▶ Multiple states (little boxes — later)

Representation of follow-up (time-split)

2 / 40



Probability

$$P(\text{surv } t_0 \rightarrow t_x | \text{entry } t_0)$$

$$\begin{aligned} &= P(\text{surv } t_0 \rightarrow t_1 | \text{entry } t_0) \\ &\times P(\text{surv } t_1 \rightarrow t_2 | \text{entry } t_1) \\ &\times P(\text{surv } t_2 \rightarrow t_x | \text{entry } t_2) \end{aligned}$$

log-Likelihood

$$0 \log(\lambda) - \lambda y$$

$$\begin{aligned} &= 0 \log(\lambda) - \lambda y_1 \\ &+ 0 \log(\lambda) - \lambda y_2 \\ &+ 0 \log(\lambda) - \lambda y_3 \end{aligned}$$

Representation of follow-up (time-split)


6 / 40

Examples: stratification by age

If follow-up is rather short, age at entry is OK for age-stratification.

If follow-up is long, use stratification by categories of **current age**, both for:


No. of events, D , and Risk time, Y .



— assuming a constant rate λ throughout.

Representation of follow-up (time-split)

3 / 40



Probability

$$P(\text{event at } t_x | \text{entry } t_0)$$

$$\begin{aligned} &= P(\text{surv } t_0 \rightarrow t_1 | \text{entry } t_0) \\ &\times P(\text{surv } t_1 \rightarrow t_2 | \text{entry } t_1) \\ &\times P(\text{event at } t_x | \text{entry } t_2) \end{aligned}$$

log-Likelihood

$$1 \log(\lambda) - \lambda y$$

$$\begin{aligned} &= 0 \log(\lambda) - \lambda y_1 \\ &+ 0 \log(\lambda) - \lambda y_2 \\ &+ 1 \log(\lambda) - \lambda y_3 \end{aligned}$$

Representation of follow-up (time-split)

7 / 40

Representation of follow-up data

A cohort or follow-up study records:

Events and Risk time.

The outcome is thus **bivariate**: (d, y)


Follow-up **data** for each individual must therefore have (at least) three variables:

Date of entry	entry	date variable
Date of exit	exit	date variable
Status at exit	fail	indicator (0/1)

Specific for each **type** of outcome.

Representation of follow-up (time-split)

4 / 40



Probability

$$P(d \text{ at } t_x | \text{entry } t_0)$$

$$\begin{aligned} &= P(\text{surv } t_0 \rightarrow t_1 | \text{entry } t_0) \\ &\times P(\text{surv } t_1 \rightarrow t_2 | \text{entry } t_1) \\ &\times P(d \text{ at } t_x | \text{entry } t_2) \end{aligned}$$


log-Likelihood

$$d \log(\lambda) - \lambda y$$

$$\begin{aligned} &= 0 \log(\lambda) - \lambda y_1 \\ &+ 0 \log(\lambda) - \lambda y_2 \\ &+ d \log(\lambda) - \lambda y_3 \end{aligned}$$

Representation of follow-up (time-split)

8 / 40



Probability

$$P(d \text{ at } t_x | \text{entry } t_0)$$

$$= P(\text{surv } t_0 \rightarrow t_1 | \text{entry } t_0)$$

$$\times P(\text{surv } t_1 \rightarrow t_2 | \text{entry } t_1)$$

$$\times P(d \text{ at } t_x | \text{entry } t_2)$$

log-Likelihood

$$d \log(\lambda) - \lambda y$$

$$= 0 \log(\lambda_1) - \lambda_1 y_1$$

$$+ 0 \log(\lambda_2) - \lambda_2 y_2$$

$$+ d \log(\lambda_3) - \lambda_3 y_3$$

— allows different rates (λ_i) in each interval

Representation of follow-up (time-split)

9/ 40

	subj. 1		subj. 2		subj. 3		Σ	
Age	Y	D	Y	D	Y	D	Y	D
0–	0.00	0	0.00	0	5.46	0	5.46	0
10–	6.94	0	1.56	0	1.12	1	8.62	1
20–	10.00	0	10.00	0	0.00	0	20.00	0
30–	10.00	0	10.00	0	0.00	0	20.00	0
40–	4.95	1	1.14	0	0.00	0	6.09	1
Σ	31.89	1	22.70	0	6.58	1	60.17	2

Representation of follow-up (time-split)

13/ 40

Dividing time into bands:

If we want to compute D and Y in intervals on some timescale we must decide on:

Origin: The date where the time scale is 0:

- ▶ Age — 0 at date of birth
- ▶ Disease duration — 0 at date of diagnosis
- ▶ Occupation exposure — 0 at date of hire

Intervals: How should it be subdivided:

- ▶ 1-year classes? 5-year classes?
- ▶ Equal length?

Aim: Separate rate in each interval

Representation of follow-up (time-split)

10/ 40

Splitting the follow-up

id	Bdate	Entry	Exit	St	risk	int
1	14/07/1952	03/08/1965	14/07/1972	0	6.9432	10
1	14/07/1952	14/07/1972	14/07/1982	0	10.0000	20
1	14/07/1952	14/07/1982	14/07/1992	0	10.0000	30
1	14/07/1952	14/07/1992	27/06/1997	1	4.9528	40
2	01/04/1954	08/09/1972	01/04/1974	0	1.5606	10
2	01/04/1954	01/04/1974	31/03/1984	0	10.0000	20
2	01/04/1954	31/03/1984	01/04/1994	0	10.0000	30
2	01/04/1954	01/04/1994	23/05/1995	0	1.1417	40
3	10/06/1987	23/12/1991	09/06/1997	0	5.4634	0
3	10/06/1987	09/06/1997	24/07/1998	1	1.1211	10

Keeping track of calendar time too?

Representation of follow-up (time-split)

14/ 40

Example: cohort with 3 persons:

Id	Bdate	Entry	Exit	St
1	14/07/1952	04/08/1965	27/06/1997	1
2	01/04/1954	08/09/1972	23/05/1995	0
3	10/06/1987	23/12/1991	24/07/1998	1

- ▶ Age bands: 10-years intervals of current age.
- ▶ Split Y for every subject accordingly
- ▶ Treat each segment as a separate unit of observation.
- ▶ Keep track of exit status in each interval.

Representation of follow-up (time-split)

11/ 40

Timescales

- ▶ A timescale is a variable that varies **deterministically** *within* each person during follow-up:
 - ▶ Age
 - ▶ Calendar time
 - ▶ Time since treatment
 - ▶ Time since relapse
- ▶ All timescales advance at the same pace (1 year per year ...)
- ▶ Note: Cumulative exposure is **not** a timescale.

Representation of follow-up (time-split)

15/ 40

Splitting the follow up

	subj. 1	subj. 2	subj. 3
Age at Entry:	13.06	18.44	4.54
Age at eXit:	44.95	41.14	11.12
Status at exit:	Dead	Alive	Dead
<hr/>			
Y	31.89	22.70	6.58
D	1	0	1

Representation of follow-up (time-split)

12/ 40

Follow-up on several timescales

- ▶ The risk-time is the same on all timescales
- ▶ Only need the entry point on each time scale:
 - ▶ Age at entry.
 - ▶ Date of entry.
 - ▶ Time since treatment at entry.
 - if time of treatment is the entry, this is 0 for all.
- ▶ **Response variable** in analysis of rates:

$$(d, y) \quad (\text{event, duration})$$
- ▶ **Covariates** in analysis of rates:
 - ▶ timescales
 - ▶ other (fixed) measurements
- ▶ ... do not confuse **duration** and **timescale** !

Representation of follow-up (time-split)


16/ 40

Follow-up data in Epi — Lexis objects

```
> thoro[1:6,1:8]
  id sex birthdat contrast injecdat volume exitdat exitstat
1  1  2  1916.609      1  1938.791    22  1976.787      1
2  2  2  1927.843      1  1943.906    80  1966.030      1
3  3  1  1902.778      1  1935.629   10  1959.719      1
4  4  1  1918.359      1  1936.396   10  1977.307      1
5  5  1  1902.931      1  1937.387   10  1945.387      1
6  6  2  1903.714      1  1937.316   20  1944.738      1
```

- Timescales of interest:
- Age
 - Calendar time
 - Time since injection

Representation of follow-up (time-split)



```
> plot( thL, 2:1, lwd=5, col=c("red","blue")[thL$contrast],
+       grid=TRUE, lty.grid=1, col.grid=gray(0.7),
+       xlim=1930+c(0,70), xaxs="i", ylim= 10+c(0,70), yaxs="i", las=1 )
> points( thL, 2:1, pch=c(NA,3)[thL$lex.Xst+1],lwd=3, cex=1.5 )
```

Representation of follow-up (time-split)

Definition of Lexis object


```
thL <- Lexis( entry = list( age = injecdat-birthdat,
                           per = injecdat,
                           tfi = 0 ),
              exit = list( per = exitdat ),
              exit.status = as.numeric(exitstat==1),
              data = thoro )
```

entry is defined on **three** timescales,
but **exit** is only needed on **one** timescale:
Follow-up time is the same on all timescales:

$$\text{exitdat} - \text{injecdat}$$

One element of entry and exit must have same name (**per**).

Representation of follow-up (time-split)



Representation of follow-up (time-split)

The looks of a Lexis object

```
> thL[1:4,1:9]
  age per tfi lex.dur lex.Cst lex.Xst lex.id
1 22.18 1938.79 0 37.99 0 1 1
2 49.54 1945.77 0 18.59 0 1 2
3 68.20 1955.18 0 1.40 0 1 3
4 20.80 1957.61 0 34.52 0 0 4
...


> summary( thL )
Transitions:
  To
From 0 1 Records: Events: Risk time: Persons:
0 504 1964 2468 1964 51934.08 2468
```

Representation of follow-up (time-split)

Splitting follow-up time

```
> spl1 <- splitLexis( thL, breaks=seq(0,100,20),
+                    time.scale="age" )
> round(spl1,1)
  age per tfi lex.dur lex.Cst lex.Xst id sex birthdat contrast injecdat vol
1 22.2 1938.8 0.0 17.8 0 0 1 2 1916.6 1 1938.8
2 40.0 1956.6 17.8 20.0 0 0 1 2 1916.6 1 1938.8
3 60.0 1976.6 37.8 0.2 0 1 1 2 1916.6 1 1938.8
4 49.5 1945.8 0.0 10.5 0 0 640 2 1896.2 1 1945.8
5 60.0 1956.2 10.5 8.1 0 1 640 2 1896.2 1 1945.8
6 68.2 1955.2 0.0 1.4 0 1 3425 1 1887.0 2 1955.2
7 20.8 1957.6 0.0 19.2 0 0 4017 2 1936.8 2 1957.6
8 40.0 1976.8 19.2 15.3 0 0 4017 2 1936.8 2 1957.6
...
```

Representation of follow-up (time-split)




```
> plot( thL, lwd=3 )
```

Representation of follow-up (time-split)

Split on another timescale

```
> spl2 <- splitLexis( spl1, time.scale="tfi",
+                     breaks=c(0,1,5,20,100) )
> round( spl2, 1 )
  lex.id age per tfi lex.dur lex.Cst lex.Xst id sex birthdat contrast inje
1 1 22.2 1938.8 0.0 1.0 0 0 1 2 1916.6 1 19
2 1 23.2 1939.8 1.0 4.0 0 0 1 2 1916.6 1 19
3 1 27.2 1943.8 5.0 12.8 0 0 1 2 1916.6 1 19
4 1 40.0 1956.6 17.8 2.2 0 0 1 2 1916.6 1 19
5 1 42.2 1958.8 20.0 17.8 0 0 1 2 1916.6 1 19
6 1 60.0 1976.6 37.8 0.2 0 1 1 2 1916.6 1 19
7 2 49.5 1945.8 0.0 1.0 0 0 640 2 1896.2 1 19
8 2 50.5 1946.8 1.0 4.0 0 0 640 2 1896.2 1 19
9 2 54.5 1950.8 5.0 5.5 0 0 640 2 1896.2 1 19
10 2 60.0 1956.2 10.5 8.1 0 1 640 2 1896.2 1 19
11 3 68.2 1955.2 0.0 1.0 0 0 3425 1 1887.0 2 19
12 3 69.2 1956.2 1.0 0.4 0 1 3425 1 1887.0 2 19
13 4 20.8 1957.6 0.0 1.0 0 0 4017 2 1936.8 2 19
14 4 21.8 1958.6 1.0 4.0 0 0 4017 2 1936.8 2 19
15 4 25.8 1962.6 5.0 14.2 0 0 4017 2 1936.8 2 19
16 4 40.0 1976.8 19.2 0.8 0 0 4017 2 1936.8 2 19
17 4 40.0 1977.6 20.0 14.5 0 0 4017 2 1936.8 2 19
```

Representation of follow-up (time-split)



Analysis of results

- d_{pi} — events in the variable: `lex.Xst`:
In the model as response: `lex.Xst==1`
- y_{pi} — risk time: `lex.dur` (duration):
In the model as offset `log(y)`, `log(lex.dur)`.
- Covariates are:
 - timescales (age, period, time in study)
 - other variables for this person (constant or *assumed* constant in each interval).
- Model rates using the covariates in `glm`:
— no difference between time-scales and other covariates.

Representation of follow-up (time-split)

28 / 40

Likelihood for a constant rate

- This setup is for a situation where it is assumed that rates are constant in each of the intervals.
- Each observation in the dataset contributes a term to the likelihood.
- Each term looks like a contribution from a Poisson variate (albeit with values only 0 or 1)
- Rates can vary along several timescales simultaneously.
- Models can include fixed covariates, as well as the timescales (the left end-points of the intervals) as continuous variables.
- The latter is where we will need splines.

Representation of follow-up (time-split)

25 / 40

Fitting a simple model

```
> stat.table( contrast,
+             list( D = sum( lex.Xst ),
+                   Y = sum( lex.dur ),
+                   Rate = ratio( lex.Xst, lex.dur, 100 ) ),
+             margin = TRUE,
+             data = spl2 )
```

contrast	D	Y	Rate
1	928.00	20094.74	4.62
2	1036.00	31839.35	3.25
Total	1964.00	51934.08	3.78

Representation of follow-up (time-split)

29 / 40

The Poisson likelihood for split data

- Split records (one per person-interval (p, i)):

$$\sum_{p,i} (d_{pi} \log(\lambda) - \lambda y_{pi}) = D \log(\lambda) - \lambda Y$$

- Assuming that the death indicator ($d_{pi} \in \{0, 1\}$) is Poisson, a model with with offset `log(ypi)` will give the same result.
- If we assume that rates are constant we get the simple expression with (D, Y)
- ... but the split data allows models that assume different rates for different (d_{pi}, y_{pi}) , so rates can vary **within** a person's follow-up.

Representation of follow-up (time-split)

26 / 40

Fitting a simple model

contrast	D	Y	Rate
1	928.00	20094.74	4.62
2	1036.00	31839.35	3.25

```
> m0 <- glm( (lex.Xst==1) ~ factor(contrast) - 1,
+           offset = log(lex.dur/100),
+           family = poisson,
+           data = spl2 )
> round( ci.exp( m0 ), 2 )
```

	exp(Est.)	2.5%	97.5%
factor(contrast)1	4.62	4.33	4.93
factor(contrast)2	3.25	3.06	3.46

Representation of follow-up (time-split)

30 / 40

Where is (d_{pi}, y_{pi}) in the split data?

```
> spl1 <- splitLexis( thL , breaks=seq(0,100,20) , time.scale="age" )
> spl2 <- splitLexis( spl1, breaks=c(0,1,5,20,100), time.scale="tfi" )
> options( digits=5 )
> spl2[1:10,1:11]
```

	lex.id	age	per	tfi	lex.dur	lex.Cst	lex.Xst	id	sex	birthdat	contrast
1	1	22.182	1938.8	0.000	1.00000	0	0	1	2	1916.6	1
2	1	23.182	1939.8	1.000	4.00000	0	0	1	2	1916.6	1
3	1	27.182	1943.8	5.000	12.81793	0	0	1	2	1916.6	1
4	1	40.000	1956.6	17.818	2.18207	0	0	1	2	1916.6	1
5	1	42.182	1958.8	20.000	17.81793	0	0	1	2	1916.6	1
6	1	60.000	1976.6	37.818	0.17796	0	1	1	2	1916.6	1
7	2	16.063	1943.9	0.000	1.00000	0	0	2	2	1927.8	1
8	2	17.063	1944.9	1.000	2.93703	0	0	2	2	1927.8	1
9	2	20.000	1947.8	3.937	1.06297	0	0	2	2	1927.8	1
10	2	21.063	1948.9	5.000	15.00000	0	0	2	2	1927.8	1

— and what are covariates for the rates?

Representation of follow-up (time-split)

27 / 40

SMR

Bendix Carstensen

Representation of follow-up

University of Tartu,

June 2017

<http://BendixCarstensen.com/SPE>

Cohorts where all are exposed

When there is no comparison group we may ask:
Do mortality rates in cohort differ from those of an **external** population, for example:

Rates from:


- Occupational cohorts
- Patient cohorts

compared with reference rates obtained from:

- Population statistics (mortality rates)
- Hospital registers (disease rates)

SMR (398)

31/ 40



SMR (398)

35/ 40

Log-likelihood for the SMR


- Cohort rates proportional to reference rates:
 $\lambda(a) = \theta \times \lambda_P(a)$ — θ the same in all age-bands.
- D_a deaths during Y_a person-years an age-band a gives the likelihood:

$$\begin{aligned} D_a \log(\lambda(a)) - \lambda(a) Y_a &= D_a \log(\theta \lambda_P(a)) - \theta \lambda_P(a) Y_a \\ &= D_a \log(\theta) + D_a \log(\lambda_P(a)) - \theta (\lambda_P(a) Y_a) \end{aligned}$$

- The constant $D_a \log(\lambda_P(a))$ does not involve θ , and so can be dropped.

SMR (398)

32/ 40



SMR (398)

36/ 40

- $\lambda_P(a) Y_a = E_a$ is the "expected" number of cases in age a , so the log-likelihood contribution from age a is:

$$D_a \log(\theta) - \theta (\lambda_P(a) Y_a) = D_a \log(\theta) - \theta (E_a)$$

- **Note:** $\lambda_P(a)$ is known for all values of a .
- The log-likelihood is similar to the log-likelihood for a rate, except that person-years Y is replaced by expected numbers, E , so:

$$\hat{\theta} = \frac{D}{\lambda_P Y} = \frac{D}{E} = \frac{\text{Observed}}{\text{Expected}} = \text{SMR}$$

- SMR is the maximum likelihood estimator of the relative mortality in the cohort.

SMR (398)

33/ 40

Split the data to fit with population data

```
> tha <- splitLexis(thL, time.scale="age", breaks=seq(0,90,5) )
> thap <- splitLexis(tha, time.scale="per", breaks=seq(1938,2038,5) )
> dim( thap )
```

[1] 23094 21

Create variables to fit with the population data

```
> thap$agr <- timeBand( thap, "age", "left" )
> thap$cal <- timeBand( thap, "per", "left" )
> round( thap[1:5,c("lex.id", "age", "agr", "per", "cal", "lex.dur", "lex.Xst", "sex")],
lex.id age agr per cal lex.dur lex.Xst sex
1 1 22.18 20 1938.79 1938 2.82 0 2
2 1 25.00 25 1941.61 1938 1.39 0 2
3 1 26.39 25 1943.00 1943 3.61 0 2
4 1 30.00 30 1946.61 1943 1.39 0 2
5 1 31.39 30 1948.00 1948 3.61 0 2
```

SMR (398)

37/ 40

Modelling the SMR in practise

- As for the rates, the SMR can be modelled using individual data.
- Response is d_i , the event indicator (lex.Xst).
- log-offset is the expected value for each piece of follow-up,
 $e_i = y_i \times \lambda_P$ (lex.dur * rate)
- λ_P is the population rate corresponding to the age, period and sex of the follow-up period y_i .

SMR (398)

34/ 40

```
> data( gmortDK )
> gmortDK[1:6,1:6]
agr per sex risk dt rt
1 0 38 1 996019 14079 14.135
2 5 38 1 802334 726 0.905
3 10 38 1 753017 600 0.797
4 15 38 1 773393 1167 1.509
5 20 38 1 813882 2031 2.495
6 25 38 1 789990 1862 2.357

> gmortDK$cal <- gmortDK$per+1900
> #
> thapx <- merge( thap, gmortDK[,c("agr", "cal", "sex", "rt")] )
> #
> thapx$E <- thapx$lex.dur * thapx$rt / 1000
```

SMR (398)

38/ 40

```
> stat.table( contrast,
+             list( D = sum( lex.Xst ),
+                   Y = sum( lex.dur ),
+                   E = sum( E ),
+                   SMR = ratio( lex.Xst, E ) ),
+             margin = TRUE,
+             data = thapx )
```

contrast	D	Y	E	SMR
1	923.00	20072.53	222.01	4.16
2	1036.00	31839.35	473.88	2.19
Total	1959.00	51911.87	695.89	2.82

SMR (898)

39 / 40

Example: Smoking and cervix cancer

Study population, measurements, follow-up, and sampling design

- ▶ Joint cohort of $N \approx 500\,000$ women from 3 Nordic biobanks.
- ▶ Follow-up: From variable entry times since 1970s till 2000.
- ▶ For each of 200 cases, 3 controls were sampled; matched for biobank, age (± 2 y), and time of entry (± 2 mo).
- ▶ Frozen sera of cases and controls analyzed for cotinine *etc.*

Main result: Adjusted OR = 1.5 (95% CI 1.1 to 2.3) for high (>242.6 ng/ml) vs. low (<3.0 ng/ml) cotinine levels.

Simen Kapeu *et al.* (2009) *Am J Epidemiol*

Nested case-control studies and case-cohort studies

1 / 30

contrast	D	Y	E	SMR
1	923.00	20072.53	222.01	4.16
2	1036.00	31839.35	473.88	2.19
Total	1959.00	51911.87	695.89	2.82

```
> m.SMR <- glm( lex.Xst ~ factor(contrast) - 1,
+             offset = log(E),
+             family = poisson,
+             data = thapx )
> round( ci.exp( m.SMR ), 2 )
```

```
exp(Est.) 2.5% 97.5%
factor(contrast)1 4.16 3.90 4.43
factor(contrast)2 2.19 2.06 2.32
```

- ▶ Analysis of SMR is like analysis of rates:
- ▶ Replace Y with E — that's all!

SMR (898)

40 / 40

Example: USF1 gene and CVD

Study population, measurements, follow-up, and sampling design

- ▶ Two FINRISK cohorts, total $N \approx 14000$ M & F, 25-64 y.
- ▶ Baseline health exam, questionnaire & blood specimens at recruitment in the 1990s – Follow-up until the end of 2003.
- ▶ Subcohort of 786 subjects sampled.
- ▶ 528 incident cases of CVD; 72 of them in the subcohort.
- ▶ Frozen blood from cases and subcohort members genotyped.

Main result: Female carriers of a high risk haplotype had a 2-fold hazard of getting CVD [95% CI: 1.2 to 3.5]

Komulainen *et al.* (2006) *PLoS Genetics*

Nested case-control studies and case-cohort studies

2 / 30

Nested case-control studies and case-cohort studies

Monday, 5 June, 2017, at 9:30–10:30

Esa Läärä & Martyn Plummer

Statistical Practice in Epidemiology with R
Tartu, Estonia, 1 to 6 June, 2017

Points to be covered

- ▶ Outcome-dependent sampling designs a.k.a. **case-control** studies vs. **full cohort** design.
- ▶ **Nested case-control** study (NCC): sampling of controls from risk-sets during follow-up of study population.
- ▶ **Matching** in selection of control subjects in NCC.
- ▶ R tools for NCC: function `ccwc()` in *Epi* for sampling controls, and `clogit()` in *survival* for model fitting.
- ▶ **Case-cohort** study (CC): sampling a subcohort from the whole cohort as it is at the start of follow-up.
- ▶ R tools for CC model fitting: function `cch()` in *survival*

Nested case-control studies and case-cohort studies

0 / 30

Full cohort design & its simple analysis

- ▶ **Full cohort design**: Data on exposure variables obtained for all subjects in a large study population.
- ▶ Summary data for crude comparison:

	Exposed	Unexposed	Total
Cases	D_1	D_0	D
Non-cases	B_1	B_0	B
Group size at start	N_1	N_0	N
Follow-up times	Y_1	Y_0	Y

- ▶ Crude estimation of **hazard ratio** $\rho = \lambda_1 / \lambda_0$: **incidence rate ratio** IR, with standard error of $\log(\text{IR})$:

$$\hat{\rho} = \text{IR} = \frac{D_1 / Y_1}{D_0 / Y_0} \quad \text{SE}[\log(\text{IR})] = \sqrt{\frac{1}{D_1} + \frac{1}{D_0}}$$

- ▶ More refined analyses: Poisson or Cox regression.

Nested case-control studies and case-cohort studies

3 / 30

Problems with full cohort design

Obtaining exposure and covariate data

- ▶ Slow and expensive in a big cohort.
- ▶ Easier with questionnaire and register data,
- ▶ Extremely costly and laborious for *e.g.*
 - measurements from biological specimens, like genotyping, antibody assays, *etc.*
 - dietary diaries,
 - occupational exposure histories in manual records.

*Can we obtain equally valid estimates of hazard ratios *etc.* with nearly as good precision by some other strategies?*

Yes – we can!

Nested case-control studies and case-cohort studies

4 / 30

Estimation of hazard ratio

The incidence rate ratio can be expressed:

$$IR = \frac{D_1/D_0}{Y_1/Y_0} = \frac{\text{cases: exposed / unexposed}}{\text{person-times: exposed / unexposed}}$$

$$= \frac{\text{exp're odds in cases}}{\text{exp're odds in p-times}} = \text{exposure odds ratio (EOR)}$$

= Exposure distribution in cases vs. that in cohort!

Implication for more efficient design:

- ▶ **Numerator:** Collect exposure data on all cases.
- ▶ **Denominator:** Estimate the ratio of person-times Y_1/Y_0 of the exposure groups in the cohort by **sampling** "control" subjects, on whom exposure is measured.

Sampling schemes or designs for controls

(A) Exclusive or traditional, "case-noncase" sampling

- ▶ Controls chosen from those $N - D$ subjects still at risk (healthy) at the end of the risk period (follow-up).

(B) Inclusive sampling or case-cohort design (CC)

- ▶ The control group – *subcohort* – is a random sample of the whole cohort (N) at start.

(C) Concurrent sampling or density sampling

- ▶ Controls drawn during the follow-up
- ▶ **Risk-set or time-matched sampling:**
A set of controls is sampled from the *risk set* at each time t of diagnosis of a new case
a.k.a. **nested case-control design (NCC)**

Case-control designs

General principle: Sampling of subjects from a given study population is *outcome-dependent*.

Data on risk factors are collected separately from

(I) **Case group:** All (or high % of) the D subjects in the study population (total N) encountering the outcome event during the follow-up.

(II) **Control group:**

- ▶ Random **sample** (simple or stratified) of C subjects ($C \ll N$) from the population.
- ▶ Eligible controls must be **bf risk** (alive, under follow-up & free of outcome) at given time(s).

Nested case-control – two meanings

- ▶ In some epidemiologic books, the term "nested case-control study" (NCC) covers jointly all variants of sampling: **(A)**, **(B)**, and **(C)**, from a cohort.

Rothman *et al.* (2008): *Modern Epidemiology*, 3rd Ed.
Dos Santos Silva (1999): *Cancer Epidemiology*. Ch 8-9

- ▶ In biostatistical texts NCC typically refers only to the variant of concurrent or density sampling **(C)**, in which *risk-set* or *time-matched* sampling is employed.

Borgan & Samuelsen (2003) in *Norsk Epidemiologi*
Langholz (2005) in *Encyclopedia of Biostatistics*.

- ▶ We shall follow the biostatisticians!

Study population in a case-control study?

Ideally: The study population comprises subjects who would be included as cases, if they got the outcome in the study


- ▶ **Cohort-based studies:** **cohort** or **closed** population of well-identified subjects under intensive follow-up for outcomes (e.g. biobank cohorts).
- ▶ **Register-based studies:** **open** or **dynamic** population in a region covered by a disease register.
- ▶ **Hospital-based studies:** dynamic **catchment** population of cases – may be hard to identify (e.g. hospitals in US).

In general, the role of control subjects is to represent the distribution of person-times by exposure variables in the underlying population from which the cases emerge.

NCC: Risk-set sampling with staggered entry

Sampling frame to select controls for a given case:


Members (\times) of the **risk set** at t_k , i.e. the population at risk at the time of diagnosis t_k of case k .



Sampled risk set contains the case and the control subjects randomly sampled from the non-cases in the risk set at t_k .

Sampling of controls – alternative frames

Illustrated in a simple longitudinal setting:
Follow-up of a cohort over a fixed risk period & no censoring.



Rodrigues, L. & Kirkwood, B.R. (1990). Case-control designs of common diseases ... *Int J Epidemiol* **19**: 205-13.

Use of different sampling schemes

(A) Exclusive sampling, or "textbook" case-control design

- ▶ Almost exclusively(!) used in studies of epidemics.
- ▶ (Studies on birth defects with *prevalent* cases.)

(B) Inclusive sampling or case-cohort design

- ▶ Good esp. for multiple outcomes, if measurements of risk factors from stored material remain stable.

(C) Concurrent or density sampling (without or with time-matching, i.e. NCC)

- ▶ The only logical design in an open population.
- ▶ Most popular in chronic diseases (Knol *et al.* 2008).

Designs **(B)** and **(C)** allow valid estimation of hazard ratios ρ without any "rare disease" assumption.

Case-control studies: Textbooks vs. real life

- ▶ Many texts in epidemiology teach outdated dogma and myths about outcome-dependent designs.
- ▶ They tend to focus on the traditional design: **exclusive sampling** of controls from the non-diseased, and claim that **odds ratio** (OR) is the only estimable parameter.
- ▶ Yet, over 60% of published case-control studies apply **concurrent sampling** or **density sampling** of controls from an **open** or **dynamic** population.
- ▶ Thus, the parameter most often estimated is the **hazard ratio** (HR) or **rate ratio** ρ .
- ▶ Still, 90% of authors really estimating HR, reported as having estimated an OR (e.g. Simen Kapeu *et al.*)

Knol *et al.* (2008). What do case-control studies estimate?
Am J Epidemiol **168**: 1073-81.

Nested case-control studies and case-cohort studies

13/ 30

Matching in case-control studies

- = **Stratified sampling** of controls, e.g. from the same region, sex, and age group as a given case
- ▶ **Frequency matching** or **group matching**:
 For cases in a specific stratum (e.g. same sex and 5-year age-group), a set of controls from a similar subgroup.
- ▶ **Individual matching** (1:1 or 1:m matching):
 For each case, choose 1 or more (rarely > 5) closely similar controls (e.g. same sex, age within ± 1 year, same neighbourhood, etc.).
- ▶ NCC: Sampling from risk-sets implies time-matching at least. Additional matching for other factors possible.
- ▶ CC: Subcohort selection involves no matching with cases.

Nested case-control studies and case-cohort studies

17/ 30

Exposure odds ratio – estimate of what?

- ▶ Crude summary of case-control data

	exposed	unexposed	total
cases	D_1	D_0	D
controls	C_1	C_0	C

- ▶ Depending on study base & sampling strategy, the empirical **exposure odds ratio** (EOR)

$$\text{EOR} = \frac{D_1/D_0}{C_1/C_0} = \frac{\text{cases: exposed / unexposed}}{\text{controls: exposed / unexposed}}$$

is a consistent estimator of

- (a) hazard ratio, (b) risk ratio, (c) risk odds ratio, (d) prevalence ratio, or (e) prevalence odds ratio

- ▶ **NB.** In case-cohort studies with variable follow-up times C_1/C_0 is substituted by \hat{Y}_1/\hat{Y}_0 , from estimated p-years.

Nested case-control studies and case-cohort studies

14/ 30

Virtues of matching

- ▶ Increases *efficiency*, if the matching factors are both
 - (i) strong *risk factors* of the disease, and
 - (ii) *correlated* with the main exposure.
- Major reason for matching.
- ▶ *Confounding* due to poorly quantified factors (sibship, neighbourhood, etc.) may be removed by close matching – only if properly analyzed.
- ▶ Biobank studies: Matching for storage time, freeze-thaw cycle & analytic batch improves *comparability of measurements* from frozen specimens
 - Match on the time of baseline measurements within the case's risk set.

Nested case-control studies and case-cohort studies

18/ 30

Precision and efficiency

With exclusive **(A)** or concurrent **(C)** sampling of controls (unmatched), estimated variance of $\log(\text{EOR})$ is

$$\widehat{\text{var}}[\log(\text{EOR})] = \frac{1}{D_1} + \frac{1}{D_0} + \frac{1}{C_1} + \frac{1}{C_0}$$

= cohort variance + sampling variance

- ▶ Depends basically on the numbers of cases, when there are ≥ 4 controls per case.
 - ▶ Is not much bigger than $1/D_1 + 1/D_0$ = variance in a full cohort study with same numbers of cases.
- ⇒ Usually < 5 controls per case is enough.
- ⇒ *These designs are very cost-efficient!*

Nested case-control studies and case-cohort studies

15/ 30

Warnings for overmatching

Matching a case with a control subject is a different issue than matching an unexposed subject to an exposed one in a cohort study – much trickier!

- ▶ Matching on an *intermediate* variable between exposure and outcome. ⇒ *Bias!*
- ▶ Matching on a *surrogate* or *correlate* of exposure, which is not a true risk factor.
 ⇒ *Loss of efficiency.*
- **Counter-matching**: Choose a control which is not similar to the case w.r.t a correlate of exposure.
 ⇒ Increases efficiency!
 - Requires appropriate weighting in the analysis.

Nested case-control studies and case-cohort studies

19/ 30

Estimation in concurrent or density sampling

- ▶ Assume first a simple situation: Prevalence of exposure in the study population is constant
- ⇒ Exposure odds C_1/C_0 among controls = consistent estimator of exposure odds Y_1/Y_0 of person-times, even if controls sampled at any time from population at risk.
- ▶ Therefore, crude $\text{EOR} = (D_1/D_0)/(C_1/C_0)$ = consistent estimator of hazard ratio $\rho = \lambda_1/\lambda_0$, and the standard error of $\log(\text{EOR})$ is as given above.
 - ▶ Yet, with a closed population or cohort, stability of exposure distribution may be unrealistic.
 - ▶ Solution: **Time-matched** sampling of controls from **risk sets**, i.e. NCC, & matched EOR to estimate HR.

Prentice & Breslow (1978), Greenland & Thomas (1982).

Nested case-control studies and case-cohort studies

16/ 30

Sampling matched controls for NCC using R

- ▶ Suppose key follow-up items are recorded for all subjects in a cohort, in which a NCC study is planned.
- ▶ Function `ccwc()` in package `Epi` can be used for risk-set sampling of controls. – Arguments:
 - `entry` : Time of entry to follow-up
 - `exit` : Time of exit from follow-up
 - `fail` : Status on exit (1 for case, 0 for censored)
 - `origin` : Origin of analysis time scale (e.g. time of birth)
 - `controls` : Number of controls to be selected for each case
 - `match` : List of matching factors
 - `data` : Cohort data frame containing input variables
- ▶ Creates a data frame for a NCC study, containing the desired number of matched controls for each case.

Nested case-control studies and case-cohort studies

20/ 30

Analysis of matched studies

- Close matching induces a new parameter for each matched case-control set or stratum.
⇒ Methods that ignore matching, like **unconditional logistic regression**, break down.
- When matching on well-defined variables (like age, sex) broader strata may be formed *post hoc*, and these factors included as covariates.
- Matching on "soft" variables (like sibship) cannot be ignored, but this can be dealt with using **conditional logistic regression**.
- Same method in matched designs **(A)**, exclusive, and **(C)**, concurrent, but the meaning of regression coefficients β_j is different:

- (A)** β_j = log of risk odds ratio (ROR),
(C) β_j = log of hazard ratio (HR).

Modelling in NCC and other matched studies

Cox proportional hazards model:

$$\lambda_i(t, x_i; \beta) = \lambda_0(t) \exp(x_{i1}\beta_1 + \dots + x_{ip}\beta_p),$$

Estimation: partial likelihood $L^P = \prod_k L_k^P$:

$$L_k^P = \exp(\eta_{ik}) / \sum_{i \in \tilde{R}(t_k)} \exp(\eta_i),$$

where $\tilde{R}(t_k)$ = **sampled risk set** at observed event time t_k , containing the case + sampled controls ($t_1 < \dots < t_D$)


⇒ Fit stratified Cox model, with $\tilde{R}(t_k)$'s as the strata.

⇔ **Conditional logistic regression**

– function `clogit()` in `survival`, wrapper of `coxph()`.

Full cohort design: Follow-up & risk sets

Each member of the cohort provides exposure data for all cases, as long as this member is at risk, *i.e.* alive, not censored & free from outcome.



Times of new cases define the **risk-sets**.


Modelling case-cohort data

Cox's PH model $\lambda_i(t) = \lambda_0(t) \exp(\eta_i)$ again, but ...

- Analysis of survival data relies on the theoretical principle that you *can't know the future*.
- Case-cohort sampling breaks this principle: cases are sampled based on what *is known* to be happening to them during follow-up.
- The union of cases and subcohort is a mixture
 - random sample of the population, and
 - "high risk" subjects who are *certain* to become cases.
- ⇒ Ordinary Cox partial likelihood is wrong.
- Overrepresentation of cases must be corrected for, by (I) **weighting**, or (II) **late entry method**.

Nested case-control (NCC) design

Whenever a new case occurs, a set of controls (here 2/case) are sampled from its risk set.



NB. A control once selected for some case can be selected as a control for another case, and can later on become a case, too.


Correction method I – weighting

The method of **weighted partial likelihood** borrows some basics ideas from survey sampling.

- Sampled risk sets
 $\tilde{R}(t_k) = \{\text{cases}\} \cup \{\text{subcohort members}\}$ at risk at t_k .
- Weights:
 - $w = 1$ for all cases (within and out of subcohort),
 - $w = N_{\text{non-cases}} / n_{\text{non-cases}} = \text{inverse of sampling-fraction } f \text{ for selecting a non-case to the subcohort.}$
- Function `coxph()` with option `weights = w` would provide consistent estimation of β parameters.
- However, the SEs must be corrected!
- R solution: Function `cch()` – a wrapper of `coxph()` – in package `survival`, with `method = "LinYing"`.

Case-cohort (CC) design

Subcohort: Sample of the whole cohort randomly selected at the outset. – Serves as reference group for all cases.



NB. A subcohort member can become a case, too.

Comparison of NCC and CC designs

- Statistical efficiency
Broadly similar in NCC and CC with about same amounts of cases and controls.
- Statistical modelling and valid inference
Straightforward for both designs with appropriate software, now widely available for CC, too
- Analysis of outcome rates on several time scales?
NCC: Only the time scale used in risk set definition can be the time variable t in the baseline hazard of PH model.
CC: Different choices for the basic time in PH model possible, because subcohort members are not time-matched to cases.

Comparison of designs (cont'd)

- ▶ Missing data
 - NCC: With close 1:1 matching, a case-control pair is lost, if either of the two has data missing on key exposure(s).
 - CC: Missingness of few data items is less serious.
- ▶ Quality and comparability of biological measurements
 - NCC: Allows each case and its controls to be matched also for analytic batch, storage time, freeze-thaw cycle, → better comparability.
 - CC: Measurements for subcohort performed at different times than for cases → differential quality & misclassification.
- ▶ Possibility for studying many diseases with same controls
 - NCC: Complicated, but possible if matching is not too refined.
 - CC: Easy, as no subcohort member is "tied" with any case.

Nested case-control studies and case-cohort studies

29/ 30

Conclusion

- ▶ "Case-controlling" is very cost-effective.
- ▶ Case-cohort design is useful especially when several outcomes are of interest, given that the measurements on stored materials remain stable during the study.
- ▶ Nested case-control design is better suited e.g. for studies involving biomarkers that can be influenced by analytic batch, long-term storage, and freeze-thaw cycles.
- ▶ Matching helps in improving efficiency and in reducing bias – but only if properly done.
- ▶ Handy R tools are available for all designs.

Nested case-control studies and case-cohort studies

30/ 30

Statistical associations vs causal effects in epidemiology

Does the exposure (smoking level, obesity, etc) have a **causal effect** on the outcome (cancer diagnosis, mortality, etc)?

is not the same question as

Is the exposure **associated** with the outcome?

Conventional statistical analysis will answer the second one, but not necessarily the first.

3/ 24

What is a causal effect?

There is more than just one way to define it.

A causal effect may be defined:

- ▶ At the **individual level**:
Would my cancer risk be different if I were a (non-)smoker?
- ▶ At the **population level**:
Would the population cancer incidence be different if the prevalence of smoking were different?
- ▶ At the **exposed subpopulation level**:
Would the cancer incidence in smokers be different if they were nonsmokers?

None of these questions is "mathematical" enough to provide a mathematically correct definition of causal effect

4/ 24

Some topics on causal inference

Krista Fischer

Estonian Genome Center, University of Tartu, Estonia

Statistical Practice in Epidemiology, Tartu 2017

1/ 24

Causal effects and counterfactuals

- ▶ Defining the causal effect of an observed exposure always involves some **counterfactual** (what-if) thinking.
- ▶ The individual causal effect can be defined as the difference
$$Y(X = 1) - Y(X = 0)$$
. where $Y(1) = Y(X = 1)$ and $Y(0) = Y(X = 0)$ are defined as individual's **potential (counterfactual) outcomes** if this individual's exposure level X were **set** to 1 or 0, respectively.
- ▶ Sometimes people (e.g J. Pearl) use the "**do**" notation to distinguish counterfactual variables from the observed ones: $Y(\text{do}(X = 1))$ and $Y(\text{do}(X = 0))$.

5/ 24

How to define a causal effect?

Causal graphs, confounding and adjustment

Causal models for observational data
Instrumental variables estimation and Mendelian randomization

Summary and references

References

2/ 24

The "naïve" association analysis

- ▶ With a binary exposure X , one would compare average outcomes in exposed and unexposed populations, finding for instance:
$$E(Y|X = 1) - E(Y|X = 0)$$
Is cancer incidence different in smokers and nonsmokers?
- ▶ This would not answer any of the causal questions stated before, as mostly:
$$E(Y|X = 1) \neq E(Y(1))$$
Cancer risk in smokers is not the same as the potential cancer risk in the population if everyone were smoking
- ▶ Similarly:
$$E(Y|X = 0) \neq E(Y(0))$$
- ▶ In most cases there is always some **unobserved confounding** present – the outcome in exposed and unexposed populations differing for other, often unmeasurable reasons than the exposure.

6/ 24


Counterfactual outcomes in different settings

- ▶ **Randomized trials**: probably the easiest – one can realistically imagine different result of a “coin flip”, determining the treatment exposure status
- ▶ **“Actionable” exposures**: smoking level, vegetable consumption, ... – interventions may alter exposure levels in future, different potential interventions would create different “counterfactual worlds”
- ▶ **Non-actionable exposures**: e.g. genotypes. It is difficult to ask “What if I had different genes?”. Still useful concept to formalize genetic effects and distinguish them from non-genetic effects.
- ▶ **Combinations**: With X – a behavioral intervention level, Z – smoking level and Y – a disease outcome, one could formalize the effect of intervention on outcome by using $Y(X, Z(X))$

7/24

More possibilities: mediation

Example: the effect of X on Y is (partly) **mediated** by Z :



$$Y = X + Z + U,$$

If you are interested in the **total effect** of X on Y – don't adjust for Z !

If you are interested in the **direct effect** of X on Y – adjust for Z .
(Only if the Z - Y association is unconfounded)


11/24

Classical/generalized regression estimates vs causal effects?

- ▶ A well-conducted **randomized trial** provides the best setting for estimation of causal effect: if exposure is randomized, it cannot be confounded
- ▶ In the presence of confounding, regression analysis provides a biased estimate for the true causal effect
- ▶ To reduce such bias, one needs to collect data on most important confounders and adjust for them
- ▶ However, too much adjustment may actually introduce more biases
- ▶ Causal graphs (Directed Acyclic Graphs, DAGs) may be extremely helpful in identifying the optimal set of adjustment variables

8/24

Actually there might be a complicated system of causal effects:




C – smoking; D – cancer

Q, S, U, W, X, Y, Z – other factors that influence cancer risks and/or smoking (genes, social background, nutrition, environment, personality, ...)

12/24

Adjustment for confounders I

“Classical” confounding: situation where third factors Z influence both, X and Y



For instance, one can assume: $X = Z + U$ and $Y = Z + V$, where U and V are independent of Z .
 X and Y are independent, conditional on Z , but marginally dependent.

One should adjust the analysis for Z , by fitting a regression model for Y with covariates X and Z . There is a causal effect between X and Y , if the effect of X is present in such model.

9/24


To check for confounding,

1. Sketch a causal graph
2. Remove all arrows corresponding to the causal effect of interest (thus, create a graph where the causal null-hypothesis would hold).
3. Remove all nodes (and corresponding edges) except those contained in the exposure (C) and outcome (D) variables and their (direct or indirect) ancestors.
4. Connect by an undirected edge every pair of nodes that both share a common child and are not already connected by a directed edge.
 - ▶ If now C and D are still associated, we say that the $C - D$ association is confounded
 - ▶ Identify the set of nodes that need to be deleted to separate C and D – inferences conditional on these variables give unconfounded estimates of the causal effects.

13/24

Adjustment may sometimes make things worse

Example: the effect of X and Y on Z :




A simple model may hold: $Z = X + Y + U$, where U is independent of X and Y .
Hence $Y = Z - X - U$.

We see the association between X and Y only when the “effect” of Z has been taken into account. But this is not the causal effect of X on Y .

One should NOT adjust the analysis for Z !

10/24

Example: mediation with confounding



Follow the algorithm to show that one should adjust the analysis for W . If W is an unobserved confounder, no valid causal inference is possible in general. However, the total effect of X on Y is estimable.

14/24

"Mendelian randomization" – genes as Instrumental Variables


- Most of the exposures of interest in chronic disease epidemiology cannot be randomized.
- Sometimes, however, nature will randomize for us: there is a SNP (Single nucleotide polymorphism, a DNA marker) that affects the exposure of interest, but not directly the outcome.
- Example: a SNP that is associated with the enzyme involved in alcohol metabolism, genetic lactose intolerance, etc.

However, the crucial assumption that the SNP cannot affect outcome in any other way than throughout the exposure, cannot be tested statistically!

15/24

Mendelian randomization example

FTO genotype, BMI and Blood Glucose level (related to Type 2 Diabetes risk; Estonian Biobank, n=3635, aged 45+)




- Average difference in Blood Glucose level (Glc, mmol/L) per BMI unit is estimated as 0.085 (SE=0.005)
- Average BMI difference per FTO risk allele is estimated as 0.50 (SE=0.09)
- Average difference in Glc level per FTO risk allele is estimated as 0.13 (SE=0.04)
- Instrumental variable estimate of the mean Glc difference per BMI unit is 0.209 (se=0.078)

19/24

General instrumental variables estimation

A causal graph with exposure X , outcome Y , confounder U and an instrument Z :



Simple regression will yield a biased estimate of the causal effect of X on Y , as the graph implies:

$$Y = \alpha_Y + \beta X + \gamma U + \epsilon, E(\epsilon|X, U) = 0$$

so $E(Y|X) = \alpha_Y + \beta X + \gamma E(U|X)$.

Thus the coefficient of X will also depend on γ and the association between X and U .

16/24

IV estimation in R (using `library(sem)`):

```

> summary(tsls(Glc~bmi, ~fto, data=fen), digits=2)

2SLS Estimates

Model Formula: Glc ~ bmi


Instruments: ~fto

Residuals:
    Min. 1st Qu.  Median    Mean 3rd Qu.    Max.
-6.3700 -1.0100 -0.0943  0.0000  0.8170 13.2000

(Intercept)   Estimate Std. Error t value Pr(>|t|)
bmi           -1.210    2.106     -0.6    0.566
fto            0.209    0.078      2.7    0.008 **
  
```

20/24

General instrumental variables estimation



$$Y = \alpha_Y + \beta X + \gamma U + \epsilon, E(\epsilon|X, U) = 0$$

How can Z help?

If $E(X|Z) = \alpha_X + \delta Z$, we get

$$E(Y|Z) = \alpha_Y + \beta E(X|Z) + \gamma E(U|Z) = \alpha_Y + \beta(\alpha_X + \delta Z) = \alpha_Y^* + \beta\delta Z.$$

As δ and $\beta\delta$ are estimable, also β becomes estimable.

17/24

IV estimation: can untestable assumptions be tested?

```

> summary(lm(Glc~bmi+fto, data=fen))
Coefficients:
            Estimate Std. Error t value Pr(>|t|)
(Intercept)  1.985    0.106    18.75  <2e-16 ***
bmi           0.088    0.004    23.36  <2e-16 ***
fto           0.049    0.030     1.66   0.097 .


For Type 2 Diabetes:
> summary(glm(t2d~bmi+fto, data=fen, family=binomial))
Coefficients:
            Estimate Std. Error z value Pr(>|z|)
(Intercept) -7.515    0.187   -40.18  <2e-16 ***
bmi           0.185    0.006    31.66  <2e-16 ***
fto           0.095    0.047     2.01   0.044 *
  
```

Does FTO have a direct effect on Glc or T2D?

A significant FTO effect would not be a proof here (nor does non-significance prove the opposite)! (WHY?)

21/24

General instrumental variables estimation



- Regress X on Z , obtain an estimate $\hat{\delta}$
- Regress Y on Z , obtain an estimate $\hat{\delta\beta}$
- Obtain $\hat{\beta} = \frac{\hat{\delta\beta}}{\hat{\delta}}$
- Valid, if Z is not associated with U and does not have any effect on Y (other than mediated by X)
- Standard error estimation is more tricky – use for instance `library(sem)`, function `tsls()`.

18/24

Can we test pleiotropy?

A naïve approach would be to fit a linear regression model for Y , with both X and G as covariates. But in this case we estimate:

$$E(Y|X, G) = \text{const} + \beta_{pl}G + \beta X + \gamma E(U|X, G).$$

It is possible to show that U is not independent of neither X nor G – therefore, the coefficient of G in the resulting model would be nonzero even if $\beta_{pl} = 0$.

Therefore there is no formal test for pleiotropy possible in the case of one genetic instrument – only biological arguments could help to decide, whether assumptions are likely to be fulfilled

In the case of multiple genetic instruments and meta-analysis, sometimes the approach of Egger regression can be used (Bowden et al, 2015). But even that is not an assumption-free method!

22/24

Summary

- ▶ There is no unique definition of “the causal effect”
- ▶ The validity of any causal effect estimates depends on the validity of the underlying assumptions.
- ▶ Adjustment for other available variables may remove (some) confounding, but it may also create more confounding. **Do not adjust for variables that may themselves be affected by the outcome.**
- ▶ Instrumental variables approaches can be helpful, but beware of assumptions!

23 / 24

Common assumptions in survival analysis

1. Subjects are **either** “healthy” **or** “diseased”, with no intermediate state.
2. The disease is **irreversible**, or requires intervention to be cured.
3. The time of disease incidence is known **exactly**.
4. The disease is **accurately** diagnosed.

These assumptions are true for **death** and many **chronic diseases**.

Multistate models (as-Harkov)

2 / 42

Some references

- ▶ A webpage by Miguel Hernan and Jamie Robins: <http://www.hsph.harvard.edu/miguel-hernan/causal-inference-book/>
- ▶ An excellent overview of Mendelian randomization: Sheehan, N., Didelez, V., Burton, P., Tobin, M., Mendelian Randomization and Causal Inference in Observational Epidemiology, PLoS Med. 2008 August; 5(8).
- ▶ A way to correct for pleiotropy bias: Bowden J, Davey Smith G, Burgess S, Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015 Apr;44(2):512-25.
- ▶ ... and how to interpret the findings (warning against overuse): Burgess, S., Thompson, S.G., Interpreting findings from Mendelian randomization using the MR-Egger method, Eur J Epidemiol (2017).

24 / 24

Is the disease a dichotomy?

A disease may be preceded by a **sub-clinical** phase before it shows symptoms.

AIDS	Decline in CD4 count
Cancer	Pre-cancerous lesions
Type 2 Diabetes	Impaired glucose tolerance

Or a disease may be classified into **degrees of severity** (mild, moderate, severe).

Multistate models (as-Harkov)

3 / 42

Multistate models

Bendix Carstensen Steno Diabetes Center
Gentofte, Denmark
<http://BendixCarstensen.com>

University of Tartu,

June 2016

<http://BendixCarstensen.com/SPE>

1 / 42

A model for cervical cancer

Invasive squamous cell cancer of the cervix is preceded by cervical intraepithelial neoplasia (CIN)



The purpose of a screening programme is to detect and treat CIN.

Aim of the modeling the **transition rates** between **states**, is to be able predict how population moves between **states**

Probabilities of **state** occupancy can be calculated.

Multistate models (as-Harkov)

4 / 42

Multistate models

Bendix Carstensen, Martyn Plummer

Multistate models

University of Tartu,

June 2016

<http://BendixCarstensen.com/SPE>

When does the disease occur?

You may need a **clinical visit** to diagnose the disease:

- ▶ examination by physician, or
- ▶ laboratory test on blood sample, or
- ▶ examination of biopsy by pathologist

We do not know what happens between consecutive visits (interval censoring).

Multistate models (as-Harkov)

5 / 42

Informative observation process?

Is the **reason** for the visit dependent on the **evolution** of disease?
Ignoring this may cause bias, like informative censoring.

Different reasons for follow-up visits:

- ▶ Fixed intervals (OK)
- ▶ Random intervals (OK)
- ▶ Doctor's care (OK)
- ▶ Self selection (**Not** OK — visits are likely to be close to event times)

Purpose of multistate modeling

- ▶ Separation of intensities of interest (model definition)
- ▶ Evaluation of covariate effects on these
- ▶ — biological interpretability of covariate effects
- ▶ Use a fitted model to compute:
- ▶ state occupancy probabilities: $P\{\text{in state } X \text{ at time } t\}$
- ▶ time spent in a given state

Markov models for multistate diseases

The natural generalization of Poisson regression to multiple disease states:

- ▶ Probability of transition between states depends **only** on current state
- ▶ — this is the **Markov** property
- ▶ \Rightarrow transition rates are constant over time
- ▶ (time-fixed) covariates may influence transition rates
- ▶ the formal Markov property is **very** restrictive
- ▶ In clinical literature "Markov model" is often used about any type of multistate model

Special multistate models

- ▶ If all transition rates depend on only one time scale
- ▶ — but possibly different (time-fixed) covariates
- ▶ \Rightarrow easy to compute state probabilities
- ▶ For this reason the most commonly available models
- ▶ but not the most realistic models.
- ▶ Realistically transition rates depend on:
- ▶ multiple time scales
- ▶ time since entry to certain states.

Components of a multistate (Markov) model

- ▶ Define the disease states.
- ▶ Define which transitions between states are allowed.
- ▶ Select covariates influencing transition rates (may be different between transitions)
- ▶ Constrain some covariate effects to be the same, or zero.
- ▶ Not a trivial task — do we want e.g.
 - ▶ cause of death
 - ▶ disease status at death

Multistate models with Lexis

Bendix Carstensen

Multistate models

University of Tartu,

June 2016

<http://BendixCarstensen.com/SPE>

Likelihood for multistate model

- ▶ The likelihood of the model depends on the probability of being in state j at time t_1 , given that you were in state i at time t_0 .
- ▶ Assume transition rates constant in small time intervals
- ▶ \Rightarrow each interval contributes terms to the likelihood:
 - ▶ one for each person at risk of a transition in the interval
 - ▶ ... for each possible transition
 - ▶ each term has the form of a Poisson likelihood contribution
 - ▶ the total likelihood for each time interval is a product of terms over persons and (possible) transitions
- ▶ Total likelihood is product of terms for all intervals
- ▶ — components **not** independent, but the total likelihood is a product; hence of the same form as the likelihood of independent Poisson variates

Example: Renal failure data from Steno

Hovind P, Tarnow L, Rossing P, Carstensen B, and Parving H-H: Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy. *Kidney Int.*, 66(3):1180–1186, 2004.

- ▶ 96 patients entering at nephrotic range albuminuria (NRA), i.e. $U\text{-alb} > 300\text{mg/day}$.
- ▶ Is remission from this condition (i.e. return to $U\text{-alb} < 300\text{mg/day}$) predictive of the prognosis?
- ▶ Endpoint of interest: Death or end stage renal disease (ESRD), i.e. dialysis or kidney transplant.

	Total	Remission	
		Yes	No
No. patients	125	32	93
No. events	77	8	69
Follow-up time (years)	1084.7	259.9	824.8


Cox-model:
Timescale: Time since nephrotic range albuminuria (NRA)
Entry: 2.5 years of GFR-measurements after NRA
Outcome: ESRD or Death

Estimates:	RR	95% c.i.	p
Fixed covariates:			
Sex (F vs. M):	0.92	(0.53,1.57)	0.740
Age at NRA (per 10 years):	1.42	(1.08,1.87)	0.011
Time-dependent covariate:			
Obtained remission:	0.28	(0.13,0.59)	0.001

Multistate models with
Lexis (ms-Lexis)


13/ 42

```
> boxes( Lr, boxpos=list(x=c(25,75),
+                         y=c(75,25)),
+        scale.R=100, show.BE=TRUE )
```



Multistate models with
Lexis (ms-Lexis)


17/ 42



Multistate models with
Lexis (ms-Lexis)

14/ 42

Illness-death model



λ : remission rate.
 μ_{NRA} : mortality/ESRD rate **before** remission.
 μ_{rem} : mortality/ESRD rate **after** remission.

Multistate models with
Lexis (ms-Lexis)

18/ 42

Features of the analysis

- Remission is included as a time-dependent variable.
- Age at entry is included as a fixed variable.

```
renal[1:5,]
id   dob   doe   dor   dox event
17 1967.944 1996.013 NA 1997.094 2
26 1959.306 1989.535 1989.814 1996.136 1
27 1962.014 1987.846 NA 1993.239 3
33 1950.747 1995.243 1995.717 2003.993 0
42 1961.296 1987.884 1996.650 2003.955 0
```

Note patient 26, 33 and 42 obtain remission.

Multistate models with
Lexis (ms-Lexis)

15/ 42

Cutting follow-up at remission: cutLexis

```
> Lc <- cutLexis( Lr, cut=Lr$dor,
+                 timescale="per",
+                 new.state="Rem",
+                 precursor.states="NRA" )
> summary( Lc )
```

Transitions:
To
From NRA Rem ESRD Records: Events: Risk time: Persons:
NRA 24 29 69 122 98 824.77 122
Rem 0 24 8 32 8 259.90 32
Sum 24 53 77 154 106 1084.67 125

Multistate models with
Lexis (ms-Lexis)

19/ 42

```
> Lr <- Lexis( entry = list( per=doe,
+                             age=doe-dob,
+                             tfi=0 ),
+              exit = list( per=dox ),
+              exit.status = event>0,
+              states = c("NRA","ESRD"),
+              data = renal )
> summary( Lr )
```


Transitions:
To
From NRA ESRD Records: Events: Risk time: Persons:
NRA 48 77 125 77 1084.67 125

Multistate models with
Lexis (ms-Lexis)

16/ 42

Showing states and FU: boxes.Lexis

```
> boxes( Lc, boxpos=list(x=c(15,85,50),
+                         y=c(85,85,20)),
+        scale.R=100, show.BE=TRUE )
```



Multistate models with
Lexis (ms-Lexis)

20/ 42


Splitting states: cutLexis

```
> Lc <- cutLexis( Lr, cut=Lr$dur,
+               timescale="per",
+               new.state="Rem",
+               precursor.states="NRA",
+               split.states=TRUE )
> summary( Lc )
```

Transitions:

From	To	NRA	Rem	ESRD	ESRD(Rem)	Records	Events	Risk time	Persons
NRA	Rem	24	29	69	0	122	98	824.77	122
Rem	ESRD	0	24	0	8	32	8	259.90	32
Sum		24	53	69	8	154	106	1084.67	125

Model for all transitions



Cox-model:


- ▶ Different timescales for transitions possible
- ▶ ... only one per transition
- ▶ No explicit representation of estimated rates.

Poisson-model:

- ▶ Timescales can be different
- ▶ Multiple timescales can be accommodated simultaneously
- ▶ Explicit representation of all transition rates

Showing states and FU: boxes.Lexis

```
> boxes( Lc, boxpos=list(x=c(15,85,15,85),
+                        y=c(85,85,20,20)), scale.R=100 )
```



Calculus of probabilities

P {Remission **before** time t }

$$= \int_0^t \lambda(u) \exp \left(- \int_0^u \lambda(s) + \mu_{NRA} ds \right) du$$

P {Being in remission **at** time t }

$$= \int_0^t \lambda(u) \exp \left(- \int_0^u \lambda(s) + \mu_{NRA}(s) ds \right) \times \exp \left(- \int_u^t \mu_{rem}(s) ds \right) du$$

Note μ_{rem} could also depend on u , time since obtained remission.

Likelihood for a general MS-model


- ▶ Product of likelihoods for each transition — each one as for a survival model
- ▶ **Risk time** is the risk time in the “From” state
- ▶ **Events** are transitions to the “To” state
- ▶ All other transitions out of “From” are treated as **censorings**
- ▶ Possible to fit models separately for each transition

Sketch of programming, assuming that λ (lambda), μ_{NRA} (mu.nra) and μ_{rem} (mu.rem) are known for each age (stored in vectors)

```
c.rem <- cumsum( lambda )
c.mort.nra <- cumsum( mu.nra )
c.mort.rem <- cumsum( mu.rem )
pr1 <- cumsum( lambda * exp( -( c.rem + c.mort.nra ) ) )

integr(t,s) <- function(t,s){
  lambda[s] * exp( -( c.rem[s] + c.mort.nra[s] ) ) *
  exp( -( c.mort.rem[t]-c.mort.rem[s] ) ) }
for( t in 1:100 ) p2[t] <- sum( integr(t,1:t) )
```

If μ_{rem} depends on time of remission, then c.mort.rem should have an extra argument.



Cox-analysis with remission as time-dependent covariate:

- ▶ Ignores λ , the remission rate.
- ▶ Assumes μ_{NRA} and μ_{rem} use the same timescale.

Calculation of integrals

The possibility of computing the state-occupancy probabilities relies on:

- ▶ Availability of closed-form formulae for the probabilities in terms of the transition rates
- ▶ Transition rates are assumed to be continuous functions of time
- ▶ Transition rates can be calculated at any point of time...
- ▶ This will allow simple calculation of the integrals from the closed-form expressions.

Semi-Markov models

- ▶ if we only have one time scale, which is common for **all** transitions
- ▶ — in practical terms: transition intensities only depend on state and the current time.
- ▶ then we can construct transition matrices for each tiny time interval

$$P_{ij}(t, t+h) = P \{ \text{state } j \text{ at } t+h \mid \text{state } i \text{ at } t \}$$

- ▶ Simple matrix multiplication then gives the matrix of transition probabilities between states between any two timepoints.

Multistate models with
Lexis (ms-Lexis)

29 / 42

State probabilities

How do we get from rates to probabilities:

- ▶ 1: Analytical calculations:
 - ▶ immensely complicated formulae
 - ▶ computationally fast (once implemented)
 - ▶ difficult to generalize
- ▶ 2: Simulation of persons' histories
 - ▶ conceptually simple
 - ▶ computationally not quite simple
 - ▶ easy to generalize
 - ▶ hard to get confidence intervals (bootstrap)

Prediction in multistate models
with simLexis (sim-Lexis)

32 / 42

Prediction in multistate models with simLexis

Bendix Carstensen


Multistate models

University of Tartu,

June 2016

<http://BendixCarstensen.com/SPE>

Simulation in a multistate model




- ▶ Simulate a "survival time" for each transition **out** of a state.
- ▶ The smallest of these is the transition time.
- ▶ Choose the corresponding transition type as transition.

Prediction in multistate models
with simLexis (sim-Lexis)

33 / 42


A more complicated multistate model



Prediction in multistate models
with simLexis (sim-Lexis)

30 / 42

Transition objects are glms




```
Tr <- list( "DN" = list( "Dead(DN)" = E1d,
                        "CVD" = E1c,
                        "ESRD" = E1e ),
            "CVD" = list( "Dead(CVD)" = E1d,
                        "ESRD(CVD)" = E1e ),
            "ESRD" = list( "Dead(ESRD)" = E1n ),
            "ESRD(CVD)" = list( "Dead(ESRD(CVD))" = E1n ) )
```

Prediction in multistate models
with simLexis (sim-Lexis)

34 / 42

A more complicated multistate model



Prediction in multistate models
with simLexis (sim-Lexis)

31 / 42

simLexis

Input required:

- ▶ A Lexis object representing the initial state of the persons to be simulated.
(lex.dur and lex.Xst will be ignored.)
- ▶ A transition object with the estimated Poisson models collected in a list of lists.

Output produced:

- ▶ A Lexis object with simulated event histories for many persons
- ▶ Use nState to count how many persons in each state at different times

Prediction in multistate models
with simLexis (sim-Lexis)

35 / 42

Using simLexis

Put one record a new Lexis object (init, say). representing a person with the desired covariates.

Must have same structure as the one used for estimation:

```
init <- subset( S5, FALSE,
  select=c(timeScales(S5),"lex.Cst",
    "dm.type","sex","hba1c",
    "sys.bt","tchol","alb",
    "smoke","bmi","gfr","hmgb",
    "ins.kg") )

init[i,"sex"] <- "M"
init[i,"age"] <- 60
...

sim1 <- simLexis( Tr1, init,
  time.pts=seq(0,25,0.2),
  N=500 )
```

Prediction in multistate models
with simLexis (sim-Lexis)

36/ 42

How many persons should you simulate?

- ▶ All probabilities have the same denominator — the initial number of persons in the simulation, N , say.
- ▶ Thus, any probability will be of the form $p = x/N$
- ▶ For small probabilities we have that:

$$\text{s.e.}(\log(\hat{p})) = (1 - p)/\sqrt{Np(1 - p)}$$

- ▶ So c.i. of the form $p \pm \text{erf}$ where:

$$\text{erf} = \exp(1.96 \times (1 - p)/\sqrt{Np(1 - p)})$$

Prediction in multistate models
with simLexis (sim-Lexis)

40/ 42

Output from simLexis

```
> summary( sim1 )


Transitions:
  To
From  DN  CVD  ES(CVD)  ES  Dead(CVD)  Dead(ES(CVD))  Dead(ES)  Dead(DN)
DN      212  81      0  145      0      0      0      0      62
CVD      0  50      7   0      24      0      0      0      0
ESRD(CVD) 0   0      3   0      0      4      0      0      0
ESRD      0   0      0  70      0      0      75      0      0
Sum     212 131     10 215     24      4     75     62

Transitions:
  To
From  Records:  Events:  Risk time:  Persons:
DN      500      288     9245.95     500
CVD      81      31     667.90      81
ESRD(CVD) 7       4     45.72       7
ESRD     145     75     891.11     145
Sum     733     398    10850.67     500
```

Prediction in multistate models
with simLexis (sim-Lexis)

37/ 42

Precision of simulated probabilities



Prediction in multistate models
with simLexis (sim-Lexis)

41/ 42

Using a simulated Lexis object — pState

```
nw1 <- pState( nState( sim1,
  at = seq(0,15,0.1),
  from = 60,
  time.scale = "age" ),
  perm = c(1:4,7:5,8) )

head( pState )
when  DN  CVD  ES(CVD)  ES  Dead(ES)  Dead(ES(CVD))  Dead(CVD)  Dead(DN)
60    1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1
60.1 0.9983 0.9986 0.9986 0.9997 0.9997 0.9997 0.9997 1
60.2 0.9954 0.9964 0.9964 0.9990 0.9990 0.9990 0.9990 1
60.3 0.9933 0.9947 0.9947 0.9981 0.9981 0.9981 0.9981 1
60.4 0.9912 0.9929 0.9929 0.9973 0.9973 0.9973 0.9974 1
60.5 0.9894 0.9913 0.9913 0.9964 0.9964 0.9964 0.9965 1

plot( pState )
```

Prediction in multistate models
with simLexis (sim-Lexis)

38/ 42

Multistate model overview


- ▶ Clarify what the relevant states are
- ▶ Allows proper estimation of transition rates
- ▶ — and relationships between them
- ▶ Separate model for each transition (arrow)
- ▶ The usual survival methodology to compute probabilities breaks down
- ▶ Simulation allows estimation of cumulative probabilities:
 - ▶ Estimate transition rates (as usual)
 - ▶ Simulate probabilities (**not** as usual)

Your turn: "Renal complications"

Prediction in multistate models
with simLexis (sim-Lexis)

42/ 42

Simulated probabilities



Prediction in multistate models
with simLexis (sim-Lexis)

39/ 42